EP4611749A2 - Composés et méthodes de traitement de cancers - Google Patents

Composés et méthodes de traitement de cancers

Info

Publication number
EP4611749A2
EP4611749A2 EP23887073.7A EP23887073A EP4611749A2 EP 4611749 A2 EP4611749 A2 EP 4611749A2 EP 23887073 A EP23887073 A EP 23887073A EP 4611749 A2 EP4611749 A2 EP 4611749A2
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
substituted alkyl
halo
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23887073.7A
Other languages
German (de)
English (en)
Inventor
Shelly LU
Ramachandran Murali
James Turkson
Francisco LOPEZ TAPIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of EP4611749A2 publication Critical patent/EP4611749A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Definitions

  • This invention relates to compounds, compositions, and methods for treating a medical condition.
  • the condition includes but is not limited to a cancer or tumor.
  • BACKGROUND All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
  • Liver cancer is the fourth most common cause of cancer related death with a 5-year survival of 18%.
  • the present invention provides a compound of Formula (A): wherein: R 1A is S, O, CH 2 , C(CH 3 ) 2 , or NR 8A , where R 8A is H or optionally substituted alkyl; R 2A is H, optionally substituted alkyl, optionally substituted carbonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl; R 3A is H, halo, optionally substituted alkyl, or OR 9A , where R 9A is H or optionally substituted alkyl; R 4A is H, halo, optionally substituted alkyl, or OR 10A , where R 10A is H or optionally substituted alkyl; R 5A is H, halo, or optionally substituted
  • the compound of Formula (A) is In some embodiments, the compound of Formula (A) is:
  • the present invention provides a pharmaceutical composition comprising an inhibitor of GIT1’s normal interactome.
  • the GIT1 inhibitor is a compound of the present invention.
  • the present invention provides a method of treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject comprising: administering a therapeutically effective amount of an inhibitor of GIT1’s normal interactome to the subject, thereby treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of the condition in the subject, wherein the condition is cancer or a condition associated with an increased expression of GIT1 and MAT2B.
  • FIG.1 depicts, in accordance with various embodiments of the invention, the structures of non-limiting examples of the inventors’ compounds that inhibit GIT1-MAT2B interaction.
  • FIG.2 depicts, in accordance with various embodiments of the invention, the inventors’ novel strategy of targeting the ANK domain of GIT1 with a molecule.
  • FIG. 3 depicts, in accordance with various embodiments of the invention, the interaction between FLAG-tagged GIT1 constructs of variable lengths and endogenous MAT2B show interaction lies between 250-420 amino acids of GIT1, corresponding to the SHD domain.
  • FIG.4 depicts, in accordance with various embodiments of the invention, the growth inhibitory effect of compound C3.
  • FIG.10 depicts, in accordance with various embodiments of the invention, compound C3 inhibits both clonogenic potential and migration in cancer cells.
  • FIG.11 depicts, in accordance with various embodiments of the invention, compound C3 disrupts MAT2B-GIT1 interaction.
  • FIG.12 depicts, in accordance with various embodiments of the invention, compound C3 disrupts interaction of MEK1/2 with GIT1, Raf, and ERK.
  • FIG.13 depicts, in accordance with various embodiments of the invention, compound C3 inhibits ERK activity and cyclin D1 expression in cancer cells but not in non-malignant cells.
  • FIG. 17C depicts, in accordance with various embodiments of the invention, higher CyclinB1 enhances CDK1/CyclinB1 binding and raises CDK1 activity to promote CDK1 nuclear entry.
  • FIG. 18A – FIG. 18C depicts, in accordance with various embodiments of the invention, CyclinB1 directly interacts with GIT1 and compound C3 promotes their interaction.
  • FIG. 19A – FIG. 19E shows that compound C3 inhibits colon cancer growth in a syngeneic (C57/BL6) subcutaneous mouse model.
  • FIG. 20A – FIG. 20C shows that compound C3 inhibits human colon cancer cells growth in liver of nude mice.
  • FIG.21A – FIG.21E shows that compound C3 inhibits colon cancer liver metastasis in immune competent mice model.
  • FIG.22A – FIG.22B shows that treatment of compound C3 reduces M2 macrophages in the tumor microenvironment.
  • FIG.23 show that compound C3 binds to GIT1-GFP and not GIT2-GFP using MST.
  • FIG. 24 depicts, in accordance with various embodiments of the invention, the predicted interactions of GIT1-Cyclin B1 using PRISM software.
  • GIT1’s hydrophobic aliphatic residues at 730, 731, and 736 are visualized in the zoomed image on the right panel.
  • FIG.25 shows that GIT1 mutation lowers interaction with cyclin B1.
  • FIG.26 shows that compound C3 inhibits growth of CRC organoid.
  • FIG.27 depicts infographics about liver and colon cancers.
  • FIG.28 depicts, in accordance with various embodiments of the invention, G protein- coupled receptor kinase-interacting protein 1 (GIT1).
  • FIG.29 depicts, in accordance with various embodiments of the invention, methionine Adenosyltransferase 2B (MAT2B).
  • FIG.31 shows that GIT1 mutation lowers interaction with cyclin B1.
  • FIG.26 shows that compound C3 inhibits growth of CRC organoid.
  • FIG.27 depicts infographics about liver and colon cancers.
  • FIG.28 depicts, in accordance with various embodiments of the invention, G protein- coupled receptor kinase-interacting protein 1 (GIT1).
  • FIG.29 depicts, in accordance with various embodiments of the invention, methionine Aden
  • FIG. 30 depicts, in accordance with various embodiments of the invention, GIT1- MAT2B as a scaffold complex that interacts with MEK and ERK to regulate MAPK activity in liver and colon cancers.
  • FIG. 31 depicts, in accordance with various embodiments of the invention, that MAT2B and GIT1 interact and are overexpressed in human HCC.
  • FIG.32 depicts, in accordance with various embodiments of the invention, the role of GIT1-MAT2B in Ras signaling.
  • FIG.33 depicts, in accordance with various embodiments of the invention, compound C3 induces a slight increase in apoptosis in cancer cells.
  • FIG.34 depicts, in accordance with various embodiments of the invention, compound C3 increases CyclinB1 content and promotes CyclinB1 phosphorylation that is associated with nuclear accumulation.
  • FIG.35 depicts, in accordance with various embodiments of the invention, compound C3-mediated stabilization of CyclinB1 is GIT1 dependent.
  • FIG.36 depicts, in accordance with various embodiments of the invention, no toxicity of compound C3 in C57/BL6 mice.
  • FIG.37 depicts, in accordance with various embodiments of the invention, a summary of the scheme of inhibition of GIT1.
  • 38D depicts, in accordance with various embodiments of the invention, compound C3 enhances GIT1-cyclin B1 interaction and cyclin B1 expression, lowers growth via GIT1.
  • In vitro translated GIT1, rMAT2B and cyclin B1 (both 0.5uG) were used to evaluate direct binding (FIG.38A).
  • FIG. 39A – FIG. 39D depicts, in accordance with various embodiments of the invention, compound C3 inhibits human CRC growth in liver.
  • RKO cells (2x10 6 ) stably expressing luciferase were injected into the liver of nude mice. Twenty days later (day 0) DMSO and compound C3 were injected intraperitoneally (ip) in FIG. 39A pilot experiment using 10mg/kd/d x 5 days, rest 2 days and repeat.
  • FIG.39B 25mg/kg daily for 5 days and imaged on day 7 using IVIS Spectrum photon-counting device optical imaging system (Xenogen, Alameda, CA.).
  • FIG.39C graph summarizes luciferase intensity from FIG.39B.
  • FIG.39D gross pictures of the livers at day 7 from FIG.39B, point to tumors *p ⁇ 0.05.
  • FIG. 40A – FIG. 40E depicts, in accordance with various embodiments of the invention, compound C3 inhibits CRC liver metastasis in immune competent mice.
  • MC38 cells 2.5 x 10 5
  • stably expressing luciferase where injected intrasplenically followed by splenectomy.
  • the terms “treat,” “treatment,” “treating,” or “amelioration” when used in reference to a disease, disorder or medical condition refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent, reverse, alleviate, ameliorate, inhibit, lessen, slow down or stop the progression or severity of a symptom or condition.
  • the term “treating” includes reducing or alleviating at least one adverse effect or symptom of a condition. Treatment is generally “effective” if one or more symptoms or clinical markers are reduced.
  • “Beneficial results” or “desired results” may include, but are in no way limited to, lessening or alleviating the severity of the disease condition, preventing the disease condition from worsening, curing the disease condition, preventing the disease condition from developing, lowering the chances of a patient developing the disease condition, decreasing morbidity and mortality, and prolonging a patient’s life or life expectancy.
  • “beneficial results” or “desired results” may be alleviation of one or more symptom(s), diminishment of extent of the deficit, stabilized (i.e., not worsening) state of cancer or tumor, delay or slowing of cancer or tumor, and amelioration or palliation of symptoms associated with cancer or tumor.
  • “Conditions” and “disease conditions,” as used herein may include, but are in no way limited to any form of malignant neoplastic cell proliferative disorders or diseases. Examples of such disorders include but are not limited to cancer and tumor.
  • a “cancer” or “tumor” as used herein refers to an uncontrolled growth of cells which interferes with the normal functioning of the bodily organs and systems, and/or all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
  • a subject that has a cancer or a tumor is a subject having objectively measurable cancer cells present in the subject’s body.
  • the term “invasive” refers to the ability to infiltrate and destroy surrounding tissue.
  • administering refers to the placement an agent as disclosed herein into a subject by a method or route which results in at least partial localization of the agents at a desired site.
  • “Route of administration” may refer to any administration pathway known in the art, including but not limited to aerosol, nasal, oral, transmucosal, transdermal, parenteral, enteral, topical or local.
  • “Parenteral” refers to a route of administration that is generally associated with injection, including intraorbital, infusion, intraarterial, intracapsular, intracardiac, intradermal, intramuscular, intraperitoneal, intrapulmonary, intraspinal, intrasternal, intrathecal, intrauterine, intravenous, subarachnoid, subcapsular, subcutaneous, transmucosal, or transtracheal.
  • sample or “biological sample” as used herein denotes a sample taken or isolated from a biological organism, e.g., a tumor sample from a subject.
  • exemplary biological samples include, but are not limited to, a biofluid sample; serum; plasma; urine; saliva; a tumor sample; a tumor biopsy and/or tissue sample etc.
  • sample also includes a mixture of the above- mentioned samples.
  • sample also includes untreated or pretreated (or pre-processed) biological samples.
  • a sample can comprise one or more cells from the subject.
  • Domestic and game animals include cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, and canine species, e.g., dog, fox, wolf.
  • patient “individual” and “subject” are used interchangeably herein.
  • the subject is mammal.
  • the mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but are not limited to these examples.
  • the methods described herein can be used to treat domesticated animals and/or pets.
  • “Mammal” as used herein refers to any member of the class Mammalia, including, without limitation, humans and nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like.
  • the term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be included within the scope of this term.
  • Non- limiting examples of electron-donating groups include OR c , NR c R d , alkyl groups, wherein R c and R d are each independently H, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl.
  • electron withdrawing group is well-known in the art and generally refers to a functional group or atom that pulls electron density towards itself, away from other portions of the molecule, e.g., through resonance and/or inductive effects.
  • C x alkyl and C x -C y alkyl are typically used where X and Y indicate the number of carbon atoms in the chain.
  • C 1 -C 6 alkyl includes alkyls that have a chain of between 1 and 6 carbons (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, neopentyl, hexyl, and the like).
  • Alkyl represented along with another radical means a straight or branched, saturated alkyl divalent radical having the number of atoms indicated or when no atoms are indicated means a bond, e.g., (C 6 -C 10 )aryl(C 0 - C 3 )alkyl includes phenyl, benzyl, phenethyl, 1-phenylethyl 3-phenylpropyl, and the like.
  • Backbone of the alkyl can be optionally inserted with one or more heteroatoms, such as N, O, or S.
  • the term “alkyl” includes heteroalkyl.
  • alkyl (or “lower alkyl”) as used throughout the specification, examples, and claims is intended to include both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having one or more substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
  • “lower alkyl” as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure.
  • “lower alkenyl” and “lower alkynyl” have similar chain lengths.
  • substituents of a substituted alkyl can include halogen, hydroxy, nitro, thiols, amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters),- CF 3 , -CN and the like.
  • alkenyl refers to unsaturated straight-chain, branched-chain or cyclic hydrocarbon radicals having at least one carbon-carbon double bond.
  • C x alkenyl and C x - C y alkenyl are typically used where X and Y indicate the number of carbon atoms in the chain.
  • C 2 -C 6 alkenyl includes alkenyls that have a chain of between 2 and 6 carbons and at least one double bond, e.g., vinyl, allyl, propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2- methylallyl, 1-hexenyl, 2-hexenyl, 3- hexenyl, and the like).
  • Alkenyl represented along with another radical means a straight or branched, alkenyl divalent radical having the number of atoms indicated.
  • alkenyl can be optionally inserted with one or more heteroatoms, such as N, O, or S.
  • heteroatoms such as N, O, or S.
  • alkynyl refers to unsaturated hydrocarbon radicals having at least one carbon-carbon triple bond.
  • C x alkynyl and C x -C y alkynyl are typically used where X and Y indicate the number of carbon atoms in the chain.
  • C 2 -C 6 alkynyl includes alkynls that have a chain of between 2 and 6 carbons and at least one triple bond, e.g., ethynyl, 1- propynyl, 2-propynyl, 1-butynyl, isopentynyl, 1,3-hexa-diyn-yl, n-hexynyl, 3-pentynyl, 1-hexen- 3-ynyl and the like.
  • Alkynyl represented along with another radical means a straight or branched, alkynyl divalent radical having the number of atoms indicated.
  • alkynyl can be optionally inserted with one or more heteroatoms, such as N, O, or S.
  • heteroatoms such as N, O, or S.
  • alkylene alkenylene
  • alkynylene alkynylene
  • Prefixes C x and C x -C y are typically used where X and Y indicate the number of carbon atoms in the chain.
  • C 1 -C 6 alkylene includes methylene, (—CH 2 — ), ethylene (—CH 2 CH 2 —), trimethylene (—CH 2 CH 2 CH 2 —), tetramethylene (— CH 2 CH 2 CH 2 CH 2 —), 2-methyltetramethylene (—CH 2 CH(CH 3 )CH 2 CH 2 —), pentamethylene (— CH 2 CH 2 CH 2 CH 2 CH 2 —) and the like).
  • Non-limiting examples of R a and R b are each independently hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl.
  • C x alkylidene and C x -C y alkylidene are typically used where X and Y indicate the number of carbon atoms in the chain.
  • heteroalkyl refers to straight or branched chain, or cyclic carbon-containing radicals, or combinations thereof, containing at least one heteroatom. Suitable heteroatoms include, but are not limited to, O, N, Si, P, Se, B, and S, wherein the phosphorous and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally quaternized. Heteroalkyls can be substituted as defined above for alkyl groups.
  • halogen or “halo” refers to an atom selected from fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).
  • halogen radioisotope or “halo radioisotope” refers to a radionuclide of an atom selected from fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).
  • iodo refers to the iodine atom (I) when it is used in the context of a halo functional group or halogen functional group or as a halo substituent or halogen substituent.
  • bromo refers to the bromine atom (Br) when it is used in the context of a halo functional group or halogen functional group or as a halo substituent or halogen substituent.
  • chloro refers to the chlorine atom (Cl) when it is used in the context of a halo functional group or halogen functional group or as a halo substituent or halogen substituent.
  • fluoro refers to the fluorine atom (F) when it is used in the context of a halo functional group or halogen functional group or as a halo substituent or halogen substituent.
  • halogen-substituted moiety or “halo-substituted moiety”, as an isolated group or part of a larger group, means an aliphatic, alicyclic, or aromatic moiety, as described herein, substituted by one or more “halo” atoms, as such terms are defined in this application.
  • halo-substituted alkyl includes haloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl and the like (e.g.
  • halosubstituted (C 1 -C 3 )alkyl includes chloromethyl, dichloromethyl, difluoromethyl, trifluoromethyl (-CF 3 ), 2,2,2-trifluoroethyl, perfluoroethyl, 2,2,2-trifluoro-l,l-dichloroethyl, and the like).
  • aryl refers to monocyclic, bicyclic, or tricyclic fused aromatic ring system.
  • C x aryl and C x -C y aryl are typically used where X and Y indicate the number of carbon atoms in the ring system.
  • C 6 -C 12 aryl includes aryls that have 6 to 12 carbon atoms in the ring system.
  • Exemplary aryl groups include, but are not limited to, pyridinyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrazolyl, pyridazinyl, pyrazinyl, triazinyl, tetrazolyl, indolyl, benzyl, phenyl, naphthyl, anthracenyl, azulenyl, fluorenyl, indanyl, indenyl, naphthyl, phenyl, tetrahydronaphthyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl,
  • heteroaryl refers to an aromatic 5-8 membered monocyclic, 8-12 membered fused bicyclic, or 11-14 membered fused tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively.
  • heteroaryls include, but are not limited to, those derived from benzo[b]furan, benzo[b] thiophene, benzimidazole, imidazo[4,5- c]pyridine, quinazoline, thieno[2,3-c]pyridine, thieno[3,2-b]pyridine, thieno[2, 3-b]pyridine, indolizine, imidazo[l,2a]pyridine, quinoline, isoquinoline, phthalazine, quinoxaline, naphthyridine, quinolizine, indole, isoindole, indazole, indoline, benzoxazole, benzopyrazole, benzothiazole, imidazo[l,5-a]pyridine, pyrazolo[l,5-a]pyridine,
  • heteroaryl groups include, but are not limited to, pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, pyridazinyl, pyrazinyl, quinolinyl, indolyl, thiazolyl, naphthyridinyl, 2-amino-4-oxo-3,4-dihydropteridin-6-yl, tetrahydroisoquinolinyl, and the like.
  • 1, 2, 3, or 4 hydrogen atoms of each ring may be substituted by a substituent.
  • cyclyl or “cycloalkyl” refers to saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons, for example, 3 to 8 carbons, and, for example, 3 to 6 carbons.
  • C x cyclyl and C x -C y cylcyl are typically used where X and Y indicate the number of carbon atoms in the ring system.
  • the cycloalkyl group additionally can be optionally substituted, e.g., with 1, 2, 3, or 4 substituents.
  • C 3 -C 10 cyclyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, cycloheptyl, cyclooctyl, bicyclo[2.2.2]octyl, adamantan-l-yl, decahydronaphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl, 2- oxobicyclo [2.2.1]hept-l-yl, and the like.
  • Aryl and heteroaryls can be optionally substituted with one or more substituents at one or more positions, for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF 3 , -CN, or the like.
  • heterocyclyl refers to a nonaromatic 5-8 membered monocyclic, 4-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively).
  • C x heterocyclyl and C x -C y heterocyclyl are typically used where X and Y indicate the number of carbon atoms in the ring system.
  • 1, 2 or 3 hydrogen atoms of each ring can be substituted by a substituent.
  • heterocyclyl groups include, but are not limited to piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, piperidyl, 4-morpholyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolizinyl, 1,4-diazaperhydroepinyl, 1,3-dioxanyl, 1,4-dioxanyl and the like.
  • fused ring refers to a ring that is bonded to another ring to form a compound having a bicyclic structure when the ring atoms that are common to both rings are directly bound to each other.
  • Non-exclusive examples of common fused rings include decalin, naphthalene, anthracene, phenanthrene, indole, furan, benzofuran, quinoline, and the like.
  • Compounds having fused ring systems can be saturated, partially saturated, cyclyl, heterocyclyl, aromatics, heteroaromatics, and the like.
  • the terms “bicyclic” and “tricyclic” refers to fused, bridged, or joined by a single bond polycyclic ring assemblies.
  • cyclylalkylene means a divalent aryl, heteroaryl, cyclyl, or heterocyclyl.
  • fused ring refers to a ring that is bonded to another ring to form a compound having a bicyclic structure when the ring atoms that are common to both rings are directly bound to each other.
  • Non-exclusive examples of common fused rings include decalin, naphthalene, anthracene, phenanthrene, indole, furan, benzofuran, quinoline, and the like.
  • Compounds having fused ring systems can be saturated, partially saturated, cyclyl, heterocyclyl, aromatics, heteroaromatics, and the like.
  • carbonyl means the radical —C(O)—.
  • carbonyl radical can be further substituted with a variety of substituents to form different carbonyl groups including acids, acid halides, amides, esters, ketones, and the like.
  • carboxy means the radical —C(O)O—. It is noted that compounds described herein containing carboxy moieties can include protected derivatives thereof, i.e., where the oxygen is substituted with a protecting group. Suitable protecting groups for carboxy moieties include benzyl, tert-butyl, and the like. The term “carboxyl” means – COOH. [0099] The term “cyano” means the radical —CN.
  • heteroatom refers to an atom that is not a carbon atom. Particular examples of heteroatoms include, but are not limited to nitrogen, oxygen, sulfur and halogens.
  • hydroxy means the radical —OH.
  • an “oxoaliphatic,” “oxoalicyclic”, or “oxoaromatic” means an aliphatic, alicyclic, or aromatic, as defined herein, substituted with a carbonyl group.
  • the carbonyl group can be an aldehyde, ketone, ester, amide, acid, or acid halide.
  • aromatic means a moiety wherein the constituent atoms make up an unsaturated ring system, all atoms in the ring system are sp2 hybridized and the total number of pi electrons is equal to 4n+2.
  • an aromatic ring canbe such that the ring atoms are only carbon atoms (e.g., aryl) or can include carbon and non-carbon atoms (e.g., heteroaryl).
  • substituted refers to independent replacement of one or more (typically 1, 2, 3, 4, or 5) of the hydrogen atoms on the substituted moiety with substituents independently selected from the group of substituents listed below in the definition for “substituents” or otherwise specified.
  • a non-hydrogen substituent can be any substituent that can be bound to an atom of the given moiety that is specified to be substituted.
  • substituents include, but are not limited to, acyl, acylamino, acyloxy, aldehyde, alicyclic, aliphatic, alkanesulfonamido, alkanesulfonyl, alkaryl, alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkylamino, alkylcarbanoyl, alkylene, alkylidene, alkylthios, alkynyl, amide, amido, amino, amino, aminoalkyl, aralkyl, aralkylsulfonamido, arenesulfonamido, arenesulfonyl, aromatic, aryl, arylamino, arylcarbanoyl, aryloxy, azido, carbamoyl, carbonyl, carbonyls (including ketones, carboxy, carboxylates, CF 3 , cyano (CN), cycloalkyl, cyclo
  • two substituents together with the carbon(s) to which they are attached to, can form a ring.
  • Substituents may be protected as necessary and any of the protecting groups commonly used in the art may be employed. Non-limiting examples of protecting groups may be found, for example, in Greene et al., Protective Groups in Organic Synthesis, 3rd Ed. (New York: Wiley, 1999).
  • the terms “alkoxyl” or “alkoxy” as used herein refers to an alkyl group, as defined above, having an oxygen radical attached thereto.
  • alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy, n-propyloxy, iso-propyloxy, n-butyloxy, iso-butyloxy, and the like.
  • An “ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as can be represented by one of -O-alkyl, -O-alkenyl, and -O-alkynyl.
  • Aroxy can be represented by –O-aryl or O- heteroaryl, wherein aryl and heteroaryl are as defined below.
  • alkoxy and aroxy groups can be substituted as described above for alkyl.
  • aralkyl refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group).
  • alkylthio refers to an alkyl group, as defined above, having a sulfur radical attached thereto. In preferred embodiments, the “alkylthio” moiety is represented by one of -S- alkyl, -S-alkenyl, and -S-alkynyl. Representative alkylthio groups include methylthio, ethylthio, and the like.
  • alkylthio also encompasses cycloalkyl groups, alkene and cycloalkene groups, and alkyne groups.
  • Arylthio refers to aryl or heteroaryl groups.
  • sulfinyl means the radical —SO—. It is noted that the sulfinyl radical can be further substituted with a variety of substituents to form different sulfinyl groups including sulfinic acids, sulfinamides, sulfinyl esters, sulfoxides, and the like.
  • sulfonyl means the radical —SO 2 —.
  • the sulfonyl radical can be further substituted with a variety of substituents to form different sulfonyl groups including sulfonic acids (-SO 3 H), sulfonamides, sulfonate esters, sulfones, and the like.
  • thiocarbonyl means the radical —C(S)—. It is noted that the thiocarbonyl radical can be further substituted with a variety of substituents to form different thiocarbonyl groups including thioacids, thioamides, thioesters, thioketones, and the like.
  • amino means -NH 2 .
  • alkylamino means a nitrogen moiety having at least one straight or branched unsaturated aliphatic, cyclyl, or heterocyclyl radicals attached to the nitrogen.
  • representative amino groups include —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —NH(C 1 -C 10 alkyl), —N(C 1 -C 10 alkyl) 2 , and the like.
  • alkylamino includes “alkenylamino,” “alkynylamino,” “cyclylamino,” and “heterocyclylamino.”
  • arylamino means a nitrogen moiety having at least one aryl radical attached to the nitrogen.
  • heteroarylamino means a nitrogen moiety having at least one heteroaryl radical attached to the nitrogen.
  • heteroaryl and —N(heteroaryl) 2 .
  • two substituents together with the nitrogen can also form a ring.
  • the compounds described herein containing amino moieties can include protected derivatives thereof. Suitable protecting groups for amino moieties include acetyl, tertbutoxycarbonyl, benzyloxycarbonyl, and the like.
  • aminoalkyl means an alkyl, alkenyl, and alkynyl as defined above, except where one or more substituted or unsubstituted nitrogen atoms (—N—) are positioned between carbon atoms of the alkyl, alkenyl, or alkynyl .
  • an (C2-C 6 ) aminoalkyl refers to a chain comprising between 2 and 6 carbons and one or more nitrogen atoms positioned between the carbon atoms.
  • alkoxyalkoxy means –O-(alkyl)-O-(alkyl), such as –OCH 2 CH 2 OCH 3 , and the like.
  • alkoxyalkyl means -(alkyl)-O-(alkyl), such as -- CH 2 OCH 3 , – CH 2 OCH 2 CH 3 , and the like.
  • aryloxy means –O-(aryl), such as –O-phenyl, –O-pyridinyl, and the like.
  • arylalkyl means -(alkyl)-(aryl), such as benzyl (i.e., –CH 2 phenyl), –CH 2 - pyrindinyl, and the like.
  • arylalkyloxy means –O-(alkyl)-(aryl), such as –O-benzyl, –O–CH 2 - pyridinyl, and the like.
  • cycloalkyloxy means –O-(cycloalkyl), such as –O-cyclohexyl, and the like.
  • cycloalkylalkyloxy means –O-(alkyl)-(cycloalkyl, such as – OCH 2 cyclohexyl, and the like.
  • aminoalkoxy means –O-(alkyl)-NH 2 , such as –OCH 2 NH 2 , –OCH 2 CH 2 NH 2 , and the like.
  • mono- or di-alkylamino means –NH(alkyl) or –N(alkyl)(alkyl), respectively, such as –NHCH 3 , –N(CH 3 ) 2 , and the like.
  • the term "mono- or di-alkylaminoalkoxy” means –O-(alkyl)-NH(alkyl) or –O-(alkyl)- N(alkyl)(alkyl), respectively, such as –OCH 2 NHCH 3 , –OCH 2 CH 2 N(CH 3 ) 2 , and the like.
  • arylamino means —NH(aryl), such as –NH-phenyl, –NH-pyridinyl, and the like.
  • arylalkylamino means —NH-(alkyl)-(aryl), such as –NH-benzyl, –NHCH 2 - pyridinyl, and the like.
  • alkylamino means —NH(alkyl), such as –NHCH 3 , –NHCH 2 CH 3 , and the like.
  • cycloalkylamino means —NH-(cycloalkyl), such as –NH-cyclohexyl, and the like.
  • cycloalkylalkylamino —NH-(alkyl)-(cycloalkyl), such as –NHCH 2 - cyclohexyl, and the like.
  • cyclic and ring refer to alicyclic or aromatic groups that may or may not be substituted and/or that may or may not be heteroatom containing, and that may be monocyclic, bicyclic, or polycyclic. In some embodiments, the ring is optionally substituted.
  • a C 1 alkyl indicates that there is one carbon atom but does not indicate what are the substituents on the carbon atom.
  • a C 1 alkyl comprises methyl (i.e., —CH3) as well as —CR a R b R c where R a , R b , and R c can each independently be hydrogen or any other substituent where the atom alpha to the carbon is a heteroatom or cyano.
  • CF 3 , CH 2 OH and CH 2 CN are all C 1 alkyls.
  • derivative refers to a chemical substance related structurally to another, i.e., an “original” substance, which can be referred to as a “parent” compound.
  • a “derivative” can be made from the structurally-related parent compound in one or more steps.
  • the general physical and chemical properties of a derivative can be similar to or different from the parent compound.
  • structures depicted herein are meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structure except for the replacement of a hydrogen atom by a deuterium or tritium, or the replacement of a carbon atom by a 13 C- or 14 C-enriched carbon are within the scope of the invention.
  • compounds of the present invention as disclosed herein may be synthesized using any synthetic method available to one of skill in the art. Non-limiting examples of synthetic methods used to prepare various embodiments of compounds of the present invention are disclosed in the Examples section herein.
  • a “pharmaceutically acceptable salt”, as used herein, is intended to encompass any compound described herein that is utilized in the form of a salt thereof, especially where the salt confers on the compound improved pharmacokinetic properties as compared to the free form of compound or a different salt form of the compound.
  • the pharmaceutically acceptable salt form can also initially confer desirable pharmacokinetic properties on the compound that it did not previously possess, and may even positively affect the pharmacodynamics of the compound with respect to its therapeutic activity in the body.
  • An example of a pharmacokinetic property that can be favorably affected is the manner in which the compound is transported across cell membranes, which in turn may directly and positively affect the absorption, distribution, biotransformation and excretion of the compound.
  • the solubility of the compound is usually dependent upon the character of the particular salt form thereof, which it utilized.
  • an aqueous solution of the compound will provide the most rapid absorption of the compound into the body of a subject being treated, while lipid solutions and suspensions, as well as solid dosage forms, will result in less rapid absorption of the compound.
  • Pharmaceutically acceptable salts include those derived from inorganic acids such as sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicyclic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like.
  • inorganic acids such as sulfuric, sulfamic, phosphoric, nitric, and the like
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic
  • Exemplary salts also include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, succinate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.
  • Suitable acids which are capable of forming salts with the compounds of the disclosure include inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid, and the like; and organic acids such as 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, 2-naphthalenesulfonic acid, 3- phenylpropionic acid, 4-methylbicyclo[2.2.2]oct-2-ene-l-carboxylic acid, 4,4’-mefhylenebis(3- hydroxy-2-ene-l-carboxylic acid), acetic acid, anthranilic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, cinnamic acid, citric acid, cyclopentanepropionic acid, ethanesulfonic acid, formic acid, fumaric acid, glucoheptonic acid
  • Suitable bases capable of forming salts with the compounds of the disclosure include inorganic bases such as sodium hydroxide, ammonium hydroxide, sodium carbonate, calcium hydroxide, potassium hydroxide and the like; and organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine, N-methylglucamine, pyridine, picoline, dicyclohexylamine, N,N’-dibezylethylenediamine, and the like), and optionally substituted ethanol-amines (e.g., ethanolamine, diethanolamine, trierhanolamine and the like).
  • inorganic bases such as sodium hydroxide, ammonium hydroxide, sodium carbonate, calcium hydroxide, potassium hydroxide and the like
  • organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethyl
  • protected derivatives means derivatives of compounds described herein in which a reactive site or sites are blocked with protecting groups. Protected derivatives are useful in the preparation of compounds or in themselves can be active. A comprehensive list of suitable protecting groups can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc.1999.
  • “Isomers” mean any compound having identical molecular formulae but differing in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”.
  • stereoisomers that are not mirror images of one another are termed “diastereomers” and stereoisomers that are nonsuperimposable mirror images are termed “enantiomers” or sometimes “optical isomers”.
  • a carbon atom bonded to four nonidentical substituents is termed a “chiral center”.
  • a compound with one chiral center has two enantiomeric forms of opposite chirality.
  • a mixture of the two enantiomeric forms is termed a “racemic mixture”.
  • a compound that has more than one chiral center has 2n-1 enantiomeric pairs, where n is the number of chiral centers.
  • Compounds with more than one chiral center may exist as ether an individual diastereomers or as a mixture of diastereomers, termed a “diastereomeric mixture”.
  • a stereoisomer may be characterized by the absolute configuration of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center.
  • Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and S-sequencing rules of Cahn, Ingold and Prelog.
  • stereochemical nomenclature methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (e.g., see “Advanced Organic Chemistry”, 4th edition, March, Jerry, John Wiley & Sons, New York, 1992).
  • enantiomer is used to describe one of a pair of molecular isomers which are mirror images of each other and non-superimposable.
  • enantiomers include “stereoisomers” (because of the different arrangement or stereochemistry around the chiral center; although all enantiomers are stereoisomers, not all stereoisomers are enantiomers) or “optical isomers” (because of the optical activity of pure enantiomers, which is the ability of different pure enantiomers to rotate planepolarized light in different directions).
  • Enantiomers generally have identical physical properties, such as melting points and boiling points, and also have identical spectroscopic properties. Enantiomers can differ from each other with respect to their interaction with plane-polarized light and with respect to biological activity.
  • R and S are used to denote the absolute configuration of the molecule about its chiral center(s).
  • the designations may appear as a prefix or as a suffix; they may or may not be separated from the isomer by a hyphen; they may or may not be hyphenated; and they may or may not be surrounded by parentheses.
  • the designations or prefixes “(+)” and “(-)” are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) meaning that the compound is levorotatory (rotates to the left). A compound prefixed with (+) is dextrorotatory (rotates to the right).
  • racemic mixture refers to a mixture of the two enantiomers of one compound.
  • An ideal racemic mixture is one wherein there is a 50:50 mixture of both enantiomers of a compound such that the optical rotation of the (+) enantiomer cancels out the optical rotation of the (-) enantiomer.
  • resolving or “resolution” when used in reference to a racemic mixture refers to the separation of a racemate into its two enantiomorphic forms (i.e., (+) and (-); 65 (R) and (S) forms).
  • the terms can also refer to enantioselective conversion of one isomer of a racemate to a product.
  • “Optional” or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.
  • the numbers expressing quantities of reagents, properties such as concentration, reaction conditions, and so forth, used to describe and claim certain embodiments of the invention are to be understood as being modified in some instances by the term “about.” Accordingly, in some embodiments, the numerical parameters set forth in the written description and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment.
  • the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The numerical values presented in some embodiments of the invention may contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements. [0150] As used herein the term “about” when used in connection with a referenced numeric indication means the referenced numeric indication plus or minus up to 5% of that referenced numeric indication, unless otherwise specifically provided for herein. For example, the language “about 50%” covers the range of 45% to 55%.
  • the term “about” when used in connection with a referenced numeric indication can mean the referenced numeric indication plus or minus up to 4%, 3%, 2%, 1%, 0.5%, or 0.25% of that referenced numeric indication, if specifically provided for in the claims.
  • Groupings of alternative elements or embodiments of the present disclosure disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability.
  • GIT1 ARF GTPase protein 1
  • HCC hepatocellular carcinoma
  • CRC colorectal cancer
  • This invention demonstrates that inhibitors of GIT1, particularly those that target the GIT1 akyrin domain, lead to impaired RAF-MEK-ERK signaling, apoptosis, and cell cycle arrest, and provides compounds, compositions, and methods for treating various conditions including but not limited to cancers and tumors.
  • One problem addressed by the invention is related to spread of cancers (for example, colorectal cancer) by metastasis. compounds, compositions, methods, and kits that inhibit cancer spread by metastasis.
  • GIT1 Inhibitor Compounds [0155] In various embodiments, the present invention provides a compound that inhibits interaction between GIT1 and MAT2B.
  • the inhibitor compound is of Formula (I): wherein: R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted; R 2 is a hydrogen, carbonyl, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted; R 3 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted; R 4 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted; and R 3 and R 4 can be joined together by either three or four methylene groups, each of which can be optionally substituted, or replaced by an oxygen or nitrogen atom.
  • R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted
  • R 2 is
  • the compound is not compound C3 (2-(8,8-Dimethyl-4-oxo- 7,10-dihydro-8H-pyrano[3’’,4’’:5’,6’]pyrido[3’,2’:4,5]thieno[3,2-d]pyrimidin-3(4H)-yl)-N-(2- furylmethyl)acetamide).
  • the compound is compound C3 (2-(8,8-Dimethyl- 4-oxo-7,10-dihydro-8H-pyrano[3’’,4’’:5’,6’]pyrido[3’,2’:4,5]thieno[3,2-d]pyrimidin-3(4H)-yl)- N-(2-furylmethyl)acetamide).
  • the compound is of Formula (II): wherein: X is a nitrogen or CH, which can be optionally substituted; Y is a hydrogen, halide, nitrile, alkyl, acyl, or hydroxyl, each of which can be optionally substituted; R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted; and R 3 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted; R 4 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted; and R 3 and R 4 can be joined together by either three or four methylene groups, each of which can be optionally substituted, or replaced by an oxygen or nitrogen atom. [0159] In some other embodiments of the
  • X is methine or nitrogen
  • R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted
  • R 3 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted
  • R 4 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted
  • R 3 and R 4 can be joined together by either three or four methylene groups, each of which can be optionally substituted, or replaced by an oxygen or nitrogen atom.
  • the compound is of Formula (IV): wherein: X is methine or nitrogen; Y is methine or nitrogen; R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted; and R 3 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted; R 4 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted; and R 3 and R 4 can be joined together by either three or four methylene groups, each of which can be optionally substituted, or replaced by an oxygen or nitrogen atom.
  • R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted
  • R 3 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocycl
  • the compound is of Formula (V): wherein: Z is an oxygen or sulfur, each of which can be optionally substituted; R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted; and R 3 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted; R 4 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted; and R 3 and R 4 can be joined together by either three or four methylene groups, each of which can be optionally substituted, or replaced by an oxygen or nitrogen atom.
  • Z is an oxygen or sulfur, each of which can be optionally substituted
  • R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted
  • R 3 is a hydrogen, alcohol, aromatic mo
  • the compound is of Formula (VI): wherein: X is an aromatic moiety, alkyl, acyl, heteroaryl, cyclyl or heterocyclyl, each of which can be optionally substituted; Y and/or Z is a hydrogen, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted; R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted; and R 3 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted; R 4 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted; and R 3 and R 4 can be joined together by either three or four methylene groups, each of which can be optionally substituted;
  • X is an aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted
  • Y is an aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted
  • R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted
  • R 3 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted
  • R 4 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted
  • R 3 and R 4 can be joined together by either three or four methylene groups, each of which can be optionally substituted, or replaced by an oxygen or nitrogen atom.
  • X is an aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, aryl, or heteroaryl, each of which can be optionally substituted
  • R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted
  • R 3 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted
  • R 4 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted
  • R 3 and R 4 can be joined together by either three or four methylene groups, each of which can be optionally substituted, or replaced by an oxygen or nitrogen atom.
  • the compound is of Formula (IX): wherein: X is a hydrogen, lower alkyl, O(CH2)2OH, or alcohol, each of which can be optionally substituted; R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted; and R 2 is a hydrogen, carbonyl, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted.
  • X is a hydrogen, lower alkyl, O(CH2)2OH, or alcohol, each of which can be optionally substituted
  • R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted
  • R 2 is a hydrogen, carbonyl, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted.
  • the compound is of Formula (X): wherein: X is a hydrogen, lower alkyl, O(CH2)2OH, or alchohol, each of which can be optionally substituted; R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted; and R 2 is a hydrogen, carbonyl, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted. [0167] In some other embodiments of the various aspects disclosed herein, the compound is of Formula (XI):
  • R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted; and R 2 is a hydrogen, carbonyl, aromaticmoiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted.
  • the GIT1 inhibitor can be a pharmaceutically acceptable salt, solvent, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative of one or more of the above compounds.
  • the IC50 of the GIT1 inhibitor is about 20 ⁇ M.
  • the IC50 of the GIT1 inhibitor is less than 30 ⁇ M, less than 25 ⁇ M, less than 20 ⁇ M, less than 15 ⁇ M, less than 10 ⁇ M, less than 5 ⁇ M, or some combination thereof.
  • GIT1 Inhibitor Compounds [0170] In various embodiments, the present invention provides a compound that inhibits interaction between GIT1 and MAT2B. [0171] In various embodiments of the present invention, the inhibitor compound is of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), or Formula (A-4).
  • the compound is not compound C3 (2-(8,8-Dimethyl-4-oxo- 7,10-dihydro-8H-pyrano[3’’,4’’:5’,6’]pyrido[3’,2’:4,5]thieno[3,2-d]pyrimidin-3(4H)-yl)-N-(2- furylmethyl)acetamide).
  • the compound is compound C3 (2-(8,8-Dimethyl-4-oxo-7,10- dihydro-8H-pyrano[3’’,4’’:5’,6’]pyrido[3’,2’:4,5]thieno[3,2-d]pyrimidin-3(4H)-yl)-N-(2- furylmethyl)acetamide).
  • Pharmaceutical Compositions [0174] In various embodiments, the present invention provides a composition that consists of, consists essentially of, or comprises an inhibitor of GIT1 expression and/or activity.
  • the composition can be used for treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject.
  • the inhibitor is a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), or a combination thereof.
  • the compound is not compound C3 (2-(8,8-Dimethyl-4-oxo-7,10-dihydro-8H- pyrano[3’’,4’’:5’,6’]pyrido[3’,2’:4,5]thieno[3,2-d]pyrimidin-3(4H)-yl)-N-(2- furylmethyl)acetamide).
  • the compound is compound C3 (2-(8,8-Dimethyl-4-oxo-7,10- dihydro-8H-pyrano[3’’,4’’:5’,6’]pyrido[3’,2’:4,5]thieno[3,2-d]pyrimidin-3(4H)-yl)-N-(2- furylmethyl)acetamide).
  • the inhibitor is a compound of Formula A, Formula A-1, Formula A-2, Formula A-3, Formula A-4, or a combination thereof.
  • the compound is not compound C3 (2-(8,8-Dimethyl-4-oxo-7,10-dihydro-8H- pyrano[3’’,4’’:5’,6’]pyrido[3’,2’:4,5]thieno[3,2-d]pyrimidin-3(4H)-yl)-N-(2- furylmethyl)acetamide).
  • the compound is compound C3 (2-(8,8-Dimethyl- 4-oxo-7,10-dihydro-8H-pyrano[3’’,4’’:5’,6’]pyrido[3’,2’:4,5]thieno[3,2-d]pyrimidin-3(4H)-yl)- N-(2-furylmethyl)acetamide).
  • the inhibitor further comprises a pharmaceutically acceptable carrier or excipient.
  • the GIT1 inhibitor inhibits contacting between GIT1 and its normal interacting proteins including MAT2B.
  • the inhibitor of GIT1 inhibits contacting between GIT1 and MEK1, MEK2, and recruitment of cRAF, BRAF, and ERK to MEK1/2. In various embodiments, the inhibitor of GIT1 promotes contacting between GIT1 and cyclin B1. In various embodiments, the inhibitor of GIT1 promotes contacting between cyclin B1 and CDK1. [0180] In various embodiments, the inhibitor may be administered 1-3 times per day, 1-7 times per week, 1-9 times per month, or more, so as to administer an effective amount of the inhibitor to the subject, where the effective amount is any one or more of the doses described herein.
  • the inhibitor is administered at about 0.1-0.5, 0.5-5, 5-10, 10-20, 20-50, 50-100, 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, or 900-1000 ⁇ M, or a combination thereof.
  • the inhibitor of GIT1 is administered for about 1- 10 days, 10-20 days, 20-30 days, 30-40 days, 40-50 days, 50-60 days, 60-70 days, 70-80 days, 80- 90 days, 90-100 days, 1-6 months, 6-12 months, or 1-5 years.
  • the inhibitor is administered once, twice, three, or more times.
  • the pharmaceutical compositions according to the invention may be formulated for delivery via any route of administration.
  • Route of administration may refer to any administration pathway known in the art, including but not limited to intratumoral, aerosol, nasal, oral, transmucosal, transdermal or parenteral.
  • Transdermal administration may be accomplished using a topical cream or ointment or by means of a transdermal patch.
  • Parenteral refers to a route of administration that is generally associated with injection, including intraorbital, infusion, intraarterial, intracapsular, intracardiac, intradermal, intramuscular, intraperitoneal, intrapulmonary, intraspinal, intrasternal, intrathecal, intrauterine, intravenous, subarachnoid, subcapsular, subcutaneous, transmucosal, or transtracheal.
  • the compositions may be in the form of solutions or suspensions for infusion or for injection, or as lyophilized powders.
  • the pharmaceutical compositions can be in the form of tablets, gel capsules, sugar-coated tablets, syrups, suspensions, solutions, powders, granules, emulsions, microspheres or nanospheres or lipid vesicles or polymer vesicles allowing controlled release.
  • the compositions may be in the form of solutions or suspensions for infusion or for injection.
  • the pharmaceutical compositions based on compounds according to the invention may be formulated for treating the skin and mucous membranes and are in the form of ointments, creams, milks, salves, powders, impregnated pads, solutions, gels, sprays, lotions or suspensions. They can also be in the form of microspheres or nanospheres or lipid vesicles or polymer vesicles or polymer patches and hydrogels allowing controlled release. These topical-route compositions can be either in anhydrous form or in aqueous form depending on the clinical indication. [0186] Via the ocular route, they may be in the form of eye drops.
  • compositions according to the invention can also contain any pharmaceutically acceptable carrier.
  • “Pharmaceutically acceptable carrier” as used herein refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting a compound of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body.
  • the carrier may be a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, or a combination thereof.
  • Each component of the carrier must be “pharmaceutically acceptable” in that it must be compatible with the other ingredients of the formulation.
  • compositions according to the invention can also be encapsulated, tableted or prepared in an emulsion or syrup for oral administration.
  • Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
  • Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, alcohols and water.
  • Solid carriers include starch, lactose, calcium sulfate, dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
  • the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulation, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
  • the preparation When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
  • the pharmaceutical compositions according to the invention may be delivered in a therapeutically effective amount. The precise therapeutically effective amount is that amount of the composition that will yield the most effective results in terms of efficacy of treatment in a given subject.
  • This amount will vary depending upon a variety of factors, including but not limited to the characteristics of the therapeutic compound (including activity, pharmacokinetics, pharmacodynamics, and bioavailability), the physiological condition of the subject (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication), the nature of the pharmaceutically acceptable carrier or carriers in the formulation, and the route of administration.
  • One skilled in the clinical and pharmacological arts will be able to determine a therapeutically effective amount through routine experimentation, for instance, by monitoring a subject’s response to administration of a compound and adjusting the dosage accordingly. For additional guidance, see Remington: The Science and Practice of Pharmacy (Gennaro ed.20th edition, Williams & Wilkins PA, USA) (2000).
  • the present invention provides a method of treating a condition in a subject.
  • method consists of or consists essentially of or comprises: administering a therapeutically effective amount of an inhibitor of GIT1 expression and/or activity to the subject, thereby treating condition in the subject.
  • the present invention provides a method of reducing the likelihood of having a condition in a subject.
  • method consists of or consists essentially of or comprises: administering a therapeutically effective amount of an inhibitor of GIT1 expression and/or activity to the subject, thereby reducing the likelihood of having the condition in the subject.
  • the present invention provides a method of reducing the severity of a condition in a subject.
  • method consists of or consists essentially of or comprises: administering a therapeutically effective amount of an inhibitor of GIT1 expression and/or activity to the subject, thereby reducing the severity of the condition in the subject.
  • the present invention provides a method of slowing the progression of a condition in a subject.
  • method consists of or consists essentially of or comprises: administering a therapeutically effective amount of an inhibitor of GIT1 expression and/or activity to the subject, thereby slowing the progression of the condition in the subject.
  • the condition is cancer having an increased expression of GIT1 and MAT2B. In various embodiments, the condition is associated with an increased expression of GIT1 and MAT2B.
  • the present invention provides a method of inhibiting GIT1 and/or MAT2B expression in a subject in need thereof, comprising administering a therapeutically effective amount of an inhibitor of GIT1 expression and/or activity to the subject, thereby inhibiting GIT1 and/or MAT2B.
  • the subject is suspected of having or has increased expression of GIT1 and/or MAT2B.
  • the subject is suspected of having or has a condition caused by the increased expression of GIT1 and/or MAT2B.
  • the condition is hepatocellular carcinoma, colorectal cancer, or cholangiocarcinoma.
  • the condition is a cancer and the cancer comprises a hepatoblastoma, a cholangiocarcinoma, or a colorectal cancer.
  • the cancer is a cancer having increased expression of GIT1 and/or MAT2B.
  • the condition is a gastrointestinal disease that comprises of a disease in the liver or the colon.
  • the condition is a gastrointestinal disease that comprises of cirrhosis, hepatitis, primary biliary cirrhosis, jaundice.
  • the condition is fibrosis.
  • the method further comprises administering at least one inhibitor that modulates the phosphorylation of GIT1.
  • the inhibitor can be provided in a separate compostion or in the same composition as the inhibitor of GIT1 expression and/or activity.
  • the method further comprises administering an additional anti- cancer therapy.
  • anti-cancer therapy refers to a therapy useful in treating cancer.
  • anti-cancer therapeutic agents include, but are limited to, e.g., surgery, radiation therapy, chemotherapeutic agents, growth inhibitory agents, cytotoxic agents, agents used in radiation therapy, anti-angiogenesis agents, apoptotic agents, anti-tubulin agents, and other agents to treat cancer, such as anti-HER-2 antibodies (e.g., HerceptinTM), anti-CD20 antibodies, an epidermal growth factor receptor (EGFR) antagonist (e.g., a tyrosine kinase inhibitor), HER1/EGFR inhibitor (e.g., erlotinib (TarcevaTM), platelet derived growth factor inhibitors (e.g., GleevecTM (Imatinib Mesylate)), a COX-2 inhibitor (e.g., celecoxib), interferons, cytokines, antagonists (e.g., neutralizing antibodies) that bind to one or more of the following targets ErbB2, ErbB3, ErbB4, PDGFR-be
  • cytotoxic agent refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells.
  • the term is intended to include radioactive isotopes (e.g. At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32 and radioactive isotopes of Lu), chemotherapeutic agents, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof.
  • chemotherapeutic agent is a chemical compound useful in the treatment of cancer.
  • chemotherapeutic agents include, but are not limited to, alkylating agents such as thiotepa and CYTOXANTM cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin
  • dynemicin including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCINTM, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino- doxorubicin and deoxydoxorubicin), epi
  • vinorelbine novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (Camptosar, CPT-11) (including the treatment regimen of irinotecan with 5-FU and leucovorin); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine; combretastatin; leucovorin (LV); oxaliplatin, including the oxaliplatin treatment regimen (FOLFOX); lapatinib (TykerbTM); inhibitors of PKC-alpha, Raf, H-Ras, EGFR (e.g., erlotinib (TarcevaTM.)) and VEGF-A that reduce cell proliferation and pharmaceutically acceptable salts, acids or derivatives of any of the above.
  • DMFO difluor
  • the chemotherapeutic agent is selected from the group consisting of Actinomycin, Alitretinoin, All-trans retinoic acid, Azacitidine, Azathioprine, Bevacizumab, Bexatotene, Bleomycin, Bortezomib, Carboplatin, Capecitabine, Cetuximab, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Epothilone, Erlotinib, Etoposide, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Imatinib, Ipilimumab, Irinotecan, Mechlorethamine, Melphalan, Mercaptopurine, Methotrexate, Mitoxantrone, Ocrelizumab,
  • cytokine is a generic term for proteins released by one cell population which act on another cell as intercellular mediators.
  • cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormone such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); epidermal growth factor; hepatic growth factor; fibroblast growth factor; prolactin; placental lactogen; tumor necrosis factor-alpha and -beta; mullerian- inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such
  • cytokine includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of the native sequence cytokines.
  • a “growth inhibitory agent” when used herein refers to a compound or composition which inhibits growth of a cell in vitro and/or in vivo. Thus, the growth inhibitory agent may be one which significantly reduces the percentage of cells in S phase. Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest.
  • Classical M-phase blockers include the vincas (vincristine and vinblastine), TAXOL®, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin.
  • Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.
  • radiation therapy is meant the use of directed gamma rays or beta rays to induce sufficient damage to a cell so as to limit its ability to function normally or to destroy the cell altogether. It will be appreciated that there will be many ways known in the art to determine the dosage and duration of treatment. Typical treatments are given as a one-time administration and typical dosages range from 10 to 200 units (Grays) per day.
  • the inhibitor can be administered using the appropriate modes of administration, for instance, the modes of administration recommended by the manufacturer or as discussed herein.
  • various routes can be utilized to administer the dual inhibitor of the claimed methods, including but not limited to administering topically, intravascularly, intravenously, intraarterially, intratumorally, intramuscularly, subcutaneously, intraperitoneally, intranasally, or orally.
  • the inhibitor is a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), or a combination thereof.
  • the subject is a human.
  • the subject in need thereof has or is at risk of having cancer.
  • the subject in need thereof has or is undergoing chemotherapy and/or irradiation.
  • the subject in need thereof has or is at risk of having a gastrointestinal disease.
  • Typical dosages of an effective amount of the GIT1 inhibitor can be in the ranges recommended by the manufacturer where known therapeutic compounds are used, and also as indicated to the skilled artisan by the in vitro responses or in vivo responses in animal models. Such dosages typically can be reduced by up to about one order of magnitude in concentration or amount without losing the relevant biological activity.
  • the actual dosage will depend upon the judgment of the physician, the condition of the patient, and the effectiveness of the therapeutic method based, for example, on the in vitro responsiveness of the relevant primary cultured cells or histocultured tissue sample, such as biopsied malignant tumors, or the responses observed in the appropriate animal models.
  • the inhibitor may be administered 1-3 times per day, 1-7 times per week, 1-9 times per month, or more, so as to administer an effective amount of the inhibitor to the subject, where the effective amount is any one or more of the doses described herein.
  • the inhibitor is administered at about 0.1-0.5, 0.5-5, 5-10, 10-20, 20-50, 50-100, 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, or 900-1000 ⁇ M, or a combination thereof.
  • the inhibitor of GIT1 is administered for about 1- 10 days, 10-20 days, 20-30 days, 30-40 days, 40-50 days, 50-60 days, 60-70 days, 70-80 days, 80- 90 days, 90-100 days, 1-6 months, 6-12 months, or 1-5 years.
  • the inhibitor is administered once, twice, three, or more times.
  • a method for inhibiting cancer cell growth consists of, consists essentially of, or comprises contacting a cancer cell with an inhibitor of GIT1 expression and/or activity and culturing under conditions and for a sufficient time to promote restriction of cancer cell growth.
  • the contacting a cancer cell can be in vitro.
  • the contacting a cancer cell can be in vivo.
  • the cancer cell originates from the liver or the colon.
  • the cancer cell is a hepatoblastoma, cholangiocarcinoma, a colorectal carcinoma, carcinomas of the breast, lung cancer, oral squamous carcinoma, stomach cancer, or a cancer having an increased expression of GIT1 and MAT2B.
  • the inhibitor of GIT1 expression and/or activity comprises a small molecule.
  • the inhibitor of GIT1 expression and/or activity is a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), or a combination thereof.
  • the inhibitor of GIT1 expression and/or activity is a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), Formula (A-4), or a combination thereof. [0218] In some embodiments, the inhibitor of GIT1 expression and/or activity is not compound C3 (2-(8,8-Dimethyl-4-oxo-7,10-dihydro-8H-pyrano[3’’,4’’:5’,6’]pyrido[3’,2’:4,5]thieno[3,2- d]pyrimidin-3(4H)-yl)-N-(2-furylmethyl)acetamide).
  • the inhibitor of GIT1 expression and/or activity is compound C3 (2-(8,8-Dimethyl-4-oxo-7,10-dihydro-8H-pyrano[3’’,4’’:5’,6’]pyrido[3’,2’:4,5]thieno[3,2- d]pyrimidin-3(4H)-yl)-N-(2-furylmethyl)acetamide).
  • Kits of the Invention [0220] In various embodiments, the present invention provides a kit for treating, preventing, or reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject.
  • the kit consists of, consists essentially of, or comprises: a GIT1 inhibitor of expression and/or activity; and instructions for using the GIT1 inhibitor to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of the condition in the subject.
  • the inhibitor is a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), or a combination thereof.
  • the inhibitor is a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), Formula (A-4), or a combination thereof.
  • the inhibitor is compound C3 (2-(8,8-Dimethyl-4-oxo-7,10- dihydro-8H-pyrano[3’’,4’’:5’,6’]pyrido[3’,2’:4,5]thieno[3,2-d]pyrimidin-3(4H)-yl)-N-(2- furylmethyl)acetamide).
  • the kit further comprises a device to administer the GIT1 inhibitor to a subject in need thereof.
  • Various Non-Limiting Embodiments of the Invention [0227] Embodiments include those listed below. [0228] Embodiment 1.
  • X is methine or nitrogen
  • Y is methine or nitrogen
  • R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted
  • R 3 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted
  • R 4 is a hydrogen, alcohol, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted
  • R 3 and R 4 can be joined together by either three or four methylene groups, each of which can be optionally substituted, or replaced by an oxygen or nitrogen atom.
  • X is a hydrogen, lower alkyl, O(CH 2 ) 2 OH, or alcohol, each of which can be optionally substituted;
  • R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted;
  • R 2 is a hydrogen, carbonyl, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted.
  • X is a hydrogen, lower alkyl, O(CH 2 ) 2 OH, or alchohol, each of which can be optionally substituted;
  • R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted;
  • R 2 is a hydrogen, carbonyl, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted.
  • R 1 is an amine, sulfur, oxygen, C(CH 3 ) 2 , or methylene, each of which can be optionally substituted; and R 2 is a hydrogen, carbonyl, aromatic moiety, alkyl, acyl, cyclyl or heterocyclyl, each of which can be optionally substituted.
  • Embodiment 12 The compound of embodiment 1, wherein the compound is a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof.
  • Embodiment 13 A pharmaceutical composition comprising an inhibitor of GIT1 expression and/or activity.
  • Embodiment 14 A pharmaceutical composition comprising an inhibitor of GIT1 expression and/or activity.
  • Embodiment 13 The pharmaceutical composition of embodiment 13, wherein the inhibitor is any one of embodiments 1-11.
  • Embodiment 15 The pharmaceutical composition of embodiment 13, further comprising a pharmaceutically acceptable carrier or excipient.
  • Embodiment 16 The pharmaceutical composition of embodiment 13, wherein the inhibitor of GIT1 inhibits contacting between GIT1 and its normal interacting proteins.
  • Embodiment 17. The method of embodiment 16, wherein GIT1’s normal interacting protein is MAT2B.
  • Embodiment 18 The pharmaceutical composition of embodiment 13, wherein the inhibitor of GIT1 inhibits contacting between GIT1 and MEK1, MEK2, and recruitment of cRAF, BRAF, and ERK to MEK1/2.
  • Embodiment 19 Embodiment 19.
  • Embodiment 13 The pharmaceutical composition of embodiment 13, wherein the inhibitor of GIT1 promotes contacting between GIT1 and cyclin B1.
  • Embodiment 20 The pharmaceutical composition of embodiment 13, wherein the inhibitor of GIT1 promotes contacting between cyclin B1 and CDK1.
  • Embodiment 21 The pharmaceutical composition of embodiment 13, wherein the composition is formulated for topical, intravascular, intravenous, intraarterial, intratumoral, intramuscular, subcutaneous, intraperitoneal, intranasal, or oral administration.
  • Embodiment 22 Embodiment 22.
  • a method of treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject comprising: administering a therapeutically effective amount of an inhibitor of GIT1 expression and/or activity to the subject, thereby treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of the condition in the subject, [0250] wherein the condition is cancer or a condition associated with an increased expression of GIT1 and MAT2B. [0251] Embodiment 23. The method of embodiment 22, wherein the condition is hepatocellular carcinoma, colorectal cancer, or cholangiocarcinoma. [0252] Embodiment 24. The method of embodiment 22, wherein the subject is a human.
  • Embodiment 25 The method of embodiment 22, wherein the inhibitor of GIT1 is administered topically, intravascularly, intravenously, intraarterially, intratumorally, intramuscularly, subcutaneously, intraperitoneally, intranasally, or orally.
  • Embodiment 26 The method of embodiment 22, wherein the inhibitor of GIT1 is a compound of any one of embodiments 1-11.
  • Embodiment 27 The method of embodiment 22, further comprising a step of administering or contacting with at least one inhibitor that modulates the phosphorylation of GIT1.
  • Embodiment 28 The method of embodiment 22, further comprising administering an additional anti-cancer therapy.
  • Embodiment 29 Embodiment 29.
  • Embodiment 30 The method of embodiment 22, wherein the subject in need thereof has or is at risk of having cancer.
  • Embodiment 30 The method of embodiment 22, wherein the subject in need thereof has or is undergoing chemotherapy and/or irradiation.
  • Embodiment 31 The method of embodiment 22, wherein the cancer comprises a hepatoblastoma, a cholangiocarcinoma, a colorectal cancer, carcinomas of the breast, lung cancer, oral squamous carcinoma, stomach cancer, or a cancer having an increased expression of GIT1 and MAT2B.
  • Embodiment 32 The method of embodiment 22, wherein the subject in need thereof has or is at risk of having a gastrointestinal disease.
  • Embodiment 33 Embodiment 33.
  • Embodiment 34 The method of embodiment 32, wherein the gastrointestinal disease comprises of Crohn’s Disease, ulcerative colitis, cirrhosis, hemochromatosis, Wilson’s disease, autoimmune hepatitis, primary biliary cirrhosis, jaundice, diverticulitis, gastritis, chronic diarrhea, and necrotizing enterocolitis.
  • Embodiment 35 The method of any one of embodiments 22-34, wherein the subject in need thereof is human.
  • Embodiment 36 The method of any one of embodiments 22-34, wherein the subject in need thereof is human.
  • a kit for treating, preventing, or reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject comprising: a GIT1 inhibitor of expression and/or activity; and instructions for using the GIT1 inhibitor to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of the condition in the subject.
  • Embodiment 37 The kit of embodiment 36, wherein the GIT1 inhibitor is any one of claims 1-11.
  • Embodiments include those listed below.
  • Compound C3 is PubChem Compound ID#663383 (2-(8,8- Dimethyl-4-oxo-7,10-dihydro-8H-pyrano[3’’,4’’:5’,6’]pyrido[3’,2’:4,5]thieno[3,2-d]pyrimidin- 3(4H)-yl)-N-(2-furylmethyl)acetamide), having the structure:
  • Embodiments include those listed below. [0270] Embodiment 1A.
  • R 1A is S, O, CH 2 , C(CH 3 ) 2 , or NR 8A , where R 8A is H or optionally substituted alkyl
  • R 2A is H, optionally substituted alkyl, optionally substituted carbonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl
  • R 3A is H, halo, optionally substituted alkyl, or OR 9A , where R 9A is H or optionally substituted alkyl
  • R 4A is H, halo, optionally substituted alkyl, or OR 10A , where R 10A is H or optionally substituted alkyl
  • R 5A is H, halo, or optionally substituted alkyl
  • R 6A is H, halo, or optionally substituted alkyl
  • Embodiment 2A The compound of embodiment 1A, wherein R 2A is: , wherein: R 11A is H, halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, optionally substituted heterocyclyl; R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; and R 16A is H, halo, or optionally substituted alkyl.
  • Embodiment 3A The compound of embodiment 2A, wherein R 2A is:
  • R 11A is H, halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, optionally substituted heterocyclyl;
  • R 12A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 13A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 14A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 15A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 16A is H, CH 3 , or CH(CH 3 ) 2 .
  • R 2A is: , wherein: R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; R 16A is H, halo, or optionally substituted alkyl; R 17A is N or CH; and R 18A is H or halo.
  • Embodiment 5A The compound of embodiment 4A, wherein R 2A is: , wherein: R 17A is N or CH; and R 18A is H or F.
  • Embodiment 6A Embodiment 6A.
  • R 2A is: , wherein: R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; and R 16A is H, halo, or optionally substituted alkyl; R 19A is N or CH; and R 20A is N or CH.
  • Embodiment 7A The compound of embodiment 6A, wherein R 2A is:
  • Embodiment 8A The compound of embodiment 2A, wherein R 2A is: , wherein: R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; R 16A is H, halo, or optionally substituted alkyl; R 21A is independently H, halo, or optionally substituted alkyl; and n is 1, 23, or 4.
  • Embodiment 9A The compound of embodiment 8A, wherein R 2A is: .
  • Embodiment 10A The compound of embodiment 8A, wherein R 2A is: .
  • R 2A is: , wherein: R 22A is halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl; R 23A is H or optionally substituted alkyl; R 24A is H, halo, or optionally substituted alkyl; R 25A is H, halo, or optionally substituted alkyl; R 26A is H, halo, or optionally substituted alkyl; and R 27A is H, halo, or optionally substituted alkyl [0280] Embodiment 11A.
  • Embodiment 12A The compound of embodiment 1A, wherein R 2A is: , wherein: R 28A is H, halo, or optionally substituted alkyl; R 29A is H, halo, or optionally substituted alkyl; R 30A is H or optionally substituted alkyl; and R 31A is H or optionally substituted alkyl; or R 30A and R 31A can be linked together to form a ring, wherein the ring is optionally substituted.
  • Embodiment 13A The compound of embodiment 12A, wherein R 2A is: , wherein: R 32A is CH or N.
  • Embodiment 14A The compound of embodiment 12A, wherein: R 2A is: , wherein: R 28A is H or CH 3 ; or , wherein: 28A R is H or CH 3 ; 2 8 wherein: R A is H or CH 3 ; or w 28A herein: R is H or CH 3 .
  • Embodiment 15A The compound of embodiment 12A, wherein: R 28A is H or CH 3 ; or , wherein: 28A R is H or CH 3 ; 2 8 wherein: R A is H or CH 3 ; or w 28A herein: R is H or CH 3 .
  • R 1A is S, O, CH 2 , C(CH 3 ) 2 , or NR 8A , where R 8A is H or optionally substituted alkyl
  • R 2A is H, optionally substituted alkyl, optionally substituted carbonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl
  • R 5A is H, halo, or optionally substituted alkyl
  • R 6A is H, halo, or optionally substituted alkyl
  • R 2A is: , wherein: R 11A is H, halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, optionally substituted heterocyclyl; R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; and R 16A is H, halo, or optionally substituted alkyl. [0289] Embodiment 20A.
  • R 11A is H, halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, optionally substituted heterocyclyl;
  • R 12A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 13A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 14A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 15A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 16A is H, CH 3 , or CH(CH 3 ) 2 .
  • R 12A is H or optionally substituted alkyl
  • R 13A is H, halo, or optionally substituted alkyl
  • R 14A is H, halo, or optionally substituted alkyl
  • R 15A is H, halo, or optionally substituted alkyl
  • R 16A is H, halo, or optionally substituted alkyl
  • R 17A is N or CH
  • R 18A is H or halo.
  • Embodiment 23A The compound of embodiment 19A, wherein R 2A is: , wherein: R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; and R 16A is H, halo, or optionally substituted alkyl; R 19A is N or CH; and R 20A is N or CH.
  • Embodiment 24A Embodiment 24A.
  • Embodiment 25A The compound of embodiment 23A, wherein R 2A is: [0294] Embodiment 25A.
  • Embodiment 26A The compound of embodiment 25A, wherein R 2A is: .
  • Embodiment 27A The compound of embodiment 18A, wherein R 2A is:
  • R 22A is halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl;
  • R 23A is H or optionally substituted alkyl;
  • R 24A is H, halo, or optionally substituted alkyl;
  • R 25A is H, halo, or optionally substituted alkyl;
  • R 26A is H, halo, or optionally substituted alkyl;
  • R 27A is H, halo, or optionally substituted alkyl.
  • Embodiment 30A The compound of embodiment 29A, wherein R 2A is: , wherein: R 32A is CH or N. [0300] Embodiment 31A.
  • R 33A is H, optionally substituted alkyl
  • R 34A is H, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl; or R 33A and R 34A can be linked together to form a ring, wherein the ring is optionally substituted.
  • Embodiment 33A The compound of embodiment 32A, wherein R 2A is: [0303] Embodiment 34A.
  • R 1A is S, O, CH 2 , C(CH 3 ) 2 , or NR 8A , where R 8A is H or optionally substituted alkyl;
  • R 2A is H, optionally substituted alkyl, optionally substituted carbonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl;
  • R 4A is H, halo, optionally substituted alkyl, or OR 10A , where R 10A is H or optionally substituted alkyl;
  • R 6A is H, halo, or optionally substituted alkyl; and
  • Embodiment 36A The compound of embodiment 35A, wherein R 2A is: , wherein: R 11A is H, halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, optionally substituted heterocyclyl; R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; and R 16A is H, halo, or optionally substituted alkyl. [0306] Embodiment 37A.
  • R 11A is H, halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, optionally substituted heterocyclyl;
  • R 12A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 13A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 14A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 15A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 16A is H, CH 3 , or CH(CH 3 ) 2 .
  • R 12A is H or optionally substituted alkyl
  • R 13A is H, halo, or optionally substituted alkyl
  • R 14A is H, halo, or optionally substituted alkyl
  • R 15A is H, halo, or optionally substituted alkyl
  • R 16A is H, halo, or optionally substituted alkyl
  • R 17A is N or CH
  • R 18A is H or halo.
  • Embodiment 40A The compound of embodiment 36A, wherein R 2A is: , wherein: R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; and R 16A is H, halo, or optionally substituted alkyl; R 19A is N or CH; and R 20A is N or CH.
  • Embodiment 41A The compound of embodiment 40A, wherein R 2A is: .
  • Embodiment 42A The compound of embodiment 36A, wherein R 2A is: , wherein: R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; R 16A is H, halo, or optionally substituted alkyl; R 21A is independently H, halo, or optionally substituted alkyl; and n is 1, 23, or 4.
  • Embodiment 43A The compound of embodiment 42A, wherein R 2A is: .
  • Embodiment 44A The compound of embodiment 35A, wherein R 2A is:
  • R 22A is halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl;
  • R 23A is H or optionally substituted alkyl;
  • R 24A is H, halo, or optionally substituted alkyl;
  • R 25A is H, halo, or optionally substituted alkyl;
  • R 26A is H, halo, or optionally substituted alkyl;
  • R 27A is H, halo, or optionally substituted alkyl.
  • Embodiment 47A The compound of embodiment 46A, wherein R 2A is: , wherein: R 32A is CH or N. [0317] Embodiment 48A.
  • R 33A is H, optionally substituted alkyl
  • R 34A is H, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl; or R 33A and R 34A can be linked together to form a ring, wherein the ring is optionally substituted.
  • Embodiment 50A The compound of embodiment 49A, wherein R 2A is: .
  • Embodiment 51A The compound of embodiment 49A, wherein R 2A is: .
  • Embodiment 52A is H, optionally substituted alkyl
  • R 34A is H, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl
  • R 33A and R 34A can be linked together to form a ring, wherein the ring is optionally substituted.
  • R 1A is S, O, CH 2 , C(CH 3 ) 2 , or NR 8A , where R 8A is H or optionally substituted alkyl
  • R 2A is H, optionally substituted alkyl, optionally substituted carbonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl
  • R 4A is H, halo, optionally substituted alkyl, or OR 10A , where R 10A is H or optionally substituted alkyl
  • R 5A is H, halo, or optionally substituted alkyl
  • R 6A is H, halo, or optionally substituted alkyl
  • R 35A is H, CH 3 , or CH 2 CH 2 OH.
  • Embodiment 53A The compound of embodiment 52A, wherein R 2A is: , wherein: R 11A is H, halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, optionally substituted heterocyclyl; R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; and R 16A is H, halo, or optionally substituted alkyl.
  • Embodiment 54A Embodiment 54A.
  • R 11A is H, halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, optionally substituted heterocyclyl;
  • R 12A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 13A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 14A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 15A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 16A is H, CH 3 , or CH(CH 3 ) 2 .
  • R 12A is H or optionally substituted alkyl
  • R 13A is H, halo, or optionally substituted alkyl
  • R 14A is H, halo, or optionally substituted alkyl
  • R 15A is H, halo, or optionally substituted alkyl
  • R 16A is H, halo, or optionally substituted alkyl
  • R 19A is N or CH
  • R 20A is N or CH.
  • R 2A is: , wherein: R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; R 16A is H, halo, or optionally substituted alkyl; R 21A is independently H, halo, or optionally substituted alkyl; and n is 1, 23, or 4. [0329] Embodiment 60A. The compound of embodiment 59A, wherein R 2A is: . [0330] Embodiment 61A. The compound of embodiment 52A, wherein R 2A is:
  • R 22A is halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl;
  • R 23A is H or optionally substituted alkyl;
  • R 24A is H, halo, or optionally substituted alkyl;
  • R 25A is H, halo, or optionally substituted alkyl;
  • R 26A is H, halo, or optionally substituted alkyl;
  • R 27A is H, halo, or optionally substituted alkyl.
  • Embodiment 64A The compound of embodiment 63A, wherein R 2A is: , wherein: R 32A is CH or N.
  • Embodiment 65A The compound of embodiment 63A, wherein: R 2A is: , wherein: R 32A is CH or N.
  • R 33A is H, optionally substituted alkyl
  • R 34A is H, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl; or R 33A and R 34A can be linked together to form a ring, wherein the ring is optionally substituted.
  • Embodiment 67A The compound of embodiment 66A, wherein R 2A is: [0337] Embodiment 68A.
  • Embodiment 69A is: [0338] Embodiment 69A.
  • R 1A is S, O, CH 2 , C(CH 3 ) 2 , or NR 8A , where R 8A is H or optionally substituted alkyl
  • R 2A is H, optionally substituted alkyl, optionally substituted carbonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl
  • R 3A is H, halo, optionally substituted alkyl, or OR 9A , where R 9A is H or optionally substituted alkyl
  • R 5A is H, halo, or optionally substituted alkyl
  • R 6A is H, halo, or optionally substituted alkyl
  • R 10A is H, CH 3 , or CH 2 CH 2 OH.
  • Embodiment 70A The compound of embodiment 69A, wherein R 2A is: , wherein: R 11A is H, halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, optionally substituted heterocyclyl; R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; and R 16A is H, halo, or optionally substituted alkyl. [0340] Embodiment 71A.
  • R 11A is H, halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, optionally substituted heterocyclyl;
  • R 12A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 13A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 14A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 15A is H, CH 3 , or CH(CH 3 ) 2 ;
  • R 16A is H, CH 3 , or CH(CH 3 ) 2 .
  • Embodiment 70A wherein: R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; R 16A is H, halo, or optionally substituted alkyl; R 17A is N or CH; and R 18A is H or halo.
  • Embodiment 73A The compound of embodiment 72A, wherein R 2A is: , wherein: R 17A is N or CH; and R 18A is H or F.
  • Embodiment 74A Embodiment 74A.
  • R 12A is H or optionally substituted alkyl
  • R 13A is H, halo, or optionally substituted alkyl
  • R 14A is H, halo, or optionally substituted alkyl
  • R 15A is H, halo, or optionally substituted alkyl
  • R 16A is H, halo, or optionally substituted alkyl
  • R 19A is N or CH
  • R 20A is N or CH.
  • R 12A is H or optionally substituted alkyl
  • R 13A is H, halo, or optionally substituted alkyl
  • R 14A is H, halo, or optionally substituted alkyl
  • R 15A is H, halo, or optionally substituted alkyl
  • R 16A is H, halo, or optionally substituted alkyl
  • R 21A is independently H, halo, or optionally substituted alkyl
  • n is 1, 23, or 4.
  • R 22A is halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl;
  • R 23A is H or optionally substituted alkyl;
  • R 24A is H, halo, or optionally substituted alkyl;
  • R 25A is H, halo, or optionally substituted alkyl;
  • R 26A is H, halo, or optionally substituted alkyl;
  • R 27A is H, halo, or optionally substituted alkyl.
  • Embodiment 81A The compound of embodiment 78A, wherein R 2A is: , wherein: R 32A is CH or N.
  • Embodiment 82A The compound of embodiment 78A, wherein R 2A is: , wherein: R 32A is CH or N.
  • Embodiment 83A The compound of embodiment 69A, wherein R 2A is: R 33A is H, optionally substituted alkyl; and R 34A is H, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl; or R 33A and R 34A can be linked together to form a ring, wherein the ring is optionally substituted.
  • Embodiment 84A The compound of embodiment 83A, wherein R 2A is: .
  • Embodiment 85A The compound of embodiment 83A, wherein R 2A is: .
  • Embodiment 86A The compound of embodiment 1A, selected from the group consisting of: ,
  • Embodiment 87A The compound of embodiment 1A, wherein the compound is: [0357] Embodiment 88A.
  • Embodiment 89A The compound of embodiment 1A, wherein the compound is: .
  • Embodiment 90A The compound of any one of embodiments 1A-89A, wherein the compound is a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof.
  • Embodiment 91A A pharmaceutical composition comprising an inhibitor of GIT1’s normal interactome.
  • Embodiment 92A The pharmaceutical composition of embodiment 91A, wherein the inhibitor of GIT1 is a compound of any one of embodiments 1A-90A.
  • Embodiment 93A The pharmaceutical composition of embodiment 91A, further comprising a pharmaceutically acceptable carrier or excipient.
  • Embodiment 94A The pharmaceutical composition of embodiment 91A, wherein the inhibitor of GIT1 inhibits contact between GIT1 and its normal interacting proteins.
  • Embodiment 95A The pharmaceutical composition of embodiment 94A, wherein one of GIT1’s normal interacting proteins is MAT2B.
  • Embodiment 96A The pharmaceutical composition of embodiment 94A, wherein one of GIT1’s normal interacting proteins is MAT2B.
  • Embodiment 91A wherein the inhibitor of GIT1 inhibits interaction between GIT1 and MEK1, MEK2, and recruitment of cRAF, BRAF, and ERK to MEK1/2.
  • Embodiment 97A The pharmaceutical composition of embodiment 91A, wherein the inhibitor of GIT1 promotes contact between GIT1 and cyclin B1.
  • Embodiment 98A The pharmaceutical composition of embodiment 91A, wherein the inhibitor of GIT1 promotes contact between cyclin B1 and CDK1.
  • Embodiment 99A Embodiment 99A.
  • composition of embodiment 91A wherein the composition is formulated for topical, intravascular, intravenous, intraarterial, intratumoral, intramuscular, subcutaneous, intraperitoneal, intranasal, or oral administration.
  • Embodiment 100A The pharmaceutical composition of embodiment 91A, wherein the inhibitor of GIT1 is: [0370] Embodiment 101A.
  • a method of treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject comprising: administering a therapeutically effective amount of an inhibitor of GIT1’s normal interactome to the subject, thereby treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of the condition in the subject, wherein the condition is cancer or a condition associated with an increased expression of GIT1 and MAT2B.
  • Embodiment 102A The method of embodiment 101A, wherein the condition is hepatocellular carcinoma, colorectal cancer, or cholangiocarcinoma.
  • Embodiment 103A Embodiment 103A.
  • Embodiment 101A wherein the subject is a human.
  • Embodiment 104A The method of embodiment 101A, wherein the inhibitor of GIT1 is administered topically, intravascularly, intravenously, intraarterially, intratumorally, intramuscularly, subcutaneously, intraperitoneally, intranasally, or orally.
  • Embodiment 105A The method of embodiment 101A, wherein the inhibitor of GIT1 is a compound of any one of embodiments 1A-90A.
  • Embodiment 106A The method of embodiment 101A, further comprising administering an additional anti-cancer therapy.
  • Embodiment 107A Embodiment 107A.
  • Embodiment 101A wherein the subject in need thereof has or is at risk of having cancer.
  • Embodiment 108A The method of embodiment 101A, wherein the subject in need thereof has or is undergoing chemotherapy and/or irradiation.
  • Embodiment 109A The method of embodiment 101A, wherein the cancer comprises a hepatoblastoma, a cholangiocarcinoma, a colorectal cancer, carcinomas of the breast, lung cancer, oral squamous carcinoma, stomach cancer, or a cancer having an increased expression of GIT1 and MAT2B.
  • Embodiment 110A Embodiment 110A.
  • Embodiment 110A wherein the subject in need thereof has or is at risk of having a gastrointestinal disease.
  • Embodiment 111A The method of embodiment 110A, wherein the gastrointestinal disease comprises of a disease in the liver or the colon.
  • Embodiment 112A The method of embodiment 110A, wherein the gastrointestinal disease comprises of Crohn’s Disease, ulcerative colitis, cirrhosis, hemochromatosis, Wilson’s disease, autoimmune hepatitis, primary biliary cirrhosis, jaundice, diverticulitis, gastritis, chronic diarrhea, and necrotizing enterocolitis.
  • Embodiment 113A Embodiment 113A.
  • Embodiment 114A The method of embodiment 101A, wherein the inhibitor of GIT1 is: (Compound C3).
  • Embodiment 115A A kit for treating, preventing, or reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject, comprising: an inhibitor of GIT1’s normal interactome; and instructions for using the GIT1 inhibitor to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of the condition in the subject.
  • Embodiment 116A Embodiment 116A.
  • kits of embodiment 115A, wherein the GIT1 inhibitor is a compound of any one of embodiments 1A-90A.
  • Embodiment 117A The kit of embodiment 115A, further comprising a device to administer the GIT1 inhibitor to a subject in need thereof.
  • Embodiment 118A The kit of embodiment 115A, wherein the GIT1 inhibitor is:
  • the present invention provides a compound of Formula (A): wherein: R 1A is S, O, CH 2 , C(CH 3 ) 2 , or NR 8A , where R 8A is H or optionally substituted alkyl; R 2A is H, optionally substituted alkyl, optionally substituted carbonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl; R 3A is H, halo, optionally substituted alkyl, or OR 9A , where R 9A is H or optionally substituted alkyl; R 4A is H, halo, optionally substituted alkyl, or OR 10A , where R 10A is H or optionally substituted alkyl; R 5A is H, halo, or optionally substituted alkyl; R 6A is H, halo, or optionally substituted alkyl; and
  • R 3A and R 5A can be linked together to form a ring, wherein the ring is optionally substituted, with the proviso that the compound of Formula (A) is not .
  • R 1A is S, O, CH 2 , C(CH 3 ) 2 , or NR 8A , where R 8A is H or optionally substituted alkyl
  • R 2A is H, optionally substituted alkyl, optionally substituted carbonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl
  • R 5A is H, halo, or optionally substituted alkyl
  • R 6A is H, halo, or optionally substituted alkyl
  • the present invention provides a compound of Formula (A- 2):
  • R 1A is S, O, CH 2 , C(CH 3 ) 2 , or NR 8A , where R 8A is H or optionally substituted alkyl;
  • R 2A is H, optionally substituted alkyl, optionally substituted carbonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl;
  • R 4A is H, halo, optionally substituted alkyl, or OR 10A , where R 10A is H or optionally substituted alkyl;
  • R 6A is H, halo, or optionally substituted alkyl; and
  • R 8A is H, CH 3 , or CH(CH 3 ) 2 .
  • R 6A is H, CH 3 or CH(CH3) 2 .
  • R 3A is CH 2 OR 35A , where R 35A is H, CH 3 , or CH 2 CH 2 OH.
  • R 2A is:
  • R 11A is H, halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, optionally substituted heterocyclyl;
  • R 12A is H or optionally substituted alkyl;
  • R 13A is H, halo, or optionally substituted alkyl;
  • R 14A is H, halo, or optionally substituted alkyl;
  • R 15A is H, halo, or optionally substituted alkyl;
  • R 16A is H, halo, or optionally substituted alkyl.
  • R 2A is: wherein: R 11A is H, halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, optionally substituted heterocyclyl; R 12A is H, CH 3 , or CH(CH 3 ) 2 ; R 13A is H, CH 3 , or CH(CH 3 ) 2 ; R 14A is H, CH 3 , or CH(CH 3 ) 2 ; R 15A is H, CH 3 , or CH(CH 3 ) 2 ; and R 16A is H, CH 3 , or CH(CH 3 ) 2 .
  • R 2A is: wherein: R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; R 16A is H, halo, or optionally substituted alkyl; R 17A is N or CH; and R 18A is H or halo. [0401] In some embodiments, R 2A is: , wherein: R 17A is N or CH; and R 18A is H or F. [0402] In some embodiments, R 2A is:
  • R 12A is H or optionally substituted alkyl
  • R 13A is H, halo, or optionally substituted alkyl
  • R 14A is H, halo, or optionally substituted alkyl
  • R 15A is H, halo, or optionally substituted alkyl
  • R 16A is H, halo, or optionally substituted alkyl
  • R 19A is N or CH
  • R 20A is N or CH.
  • R 2A is: [0404] In some embodiments, R 2A is: wherein: R 12A is H or optionally substituted alkyl; R 13A is H, halo, or optionally substituted alkyl; R 14A is H, halo, or optionally substituted alkyl; R 15A is H, halo, or optionally substituted alkyl; R 16A is H, halo, or optionally substituted alkyl; R 21A is independently H, halo, or optionally substituted alkyl; and n is 1, 23, or 4.
  • R 2A is: [0406] In some embodiments, R 2A is: wherein: R 22A is halo, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl; R 23A is H or optionally substituted alkyl; R 24A is H, halo, or optionally substituted alkyl; R 25A is H, halo, or optionally substituted alkyl; R 26A is H, halo, or optionally substituted alkyl; and R 27A is H, halo, or optionally substituted alkyl. [0407] In some embodiments, R 2A is:
  • R 22A is: [0408] In some embodiments, R 2A is: wherein: R 28A is H, halo, or optionally substituted alkyl; R 29A is H, halo, or optionally substituted alkyl; R 30A is H or optionally substituted alkyl; and R 31A is H or optionally substituted alkyl; or R 30A and R 31A can be linked together to form a ring, wherein the ring is optionally substituted. [0409] In some embodiments, R 2A is: , wherein: R 32A is CH or N. [0410] In some embodiments, R 2A is: wherei 28A n: R is H or CH 3 ; or wherein: R 28A is H or CH 3 ; where 28A in: R is H or CH 3 ; or
  • R 2A is: wherein, R 33A is H, optionally substituted alkyl; and R 34A is H, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cyclyl, or optionally substituted heterocyclyl; or R 33A and R 34A can be linked together to form a ring, wherein the ring is optionally substituted.
  • R 2A is:
  • R 2A is: [0414] In some embodiments, R 2A is:
  • R 2A is: [0416] In some embodiments, R 2A is: . [0417] In some embodiments, the compound of Formula (A) is: [0418] In some embodiments, the compound of Formula (A) is not: [0419] In some embodiments, the compound of Formula (A) is: ,
  • the compound of Formula (A) is: [0421] In some embodiments, the compound of Formula (A) is:
  • the compound of Formula (A) is:
  • the compound of Formula (A-1) is: [0424] In some embodiments, the compound of Formula (A-1) is not: [0425] In some embodiments, the compound of Formula (A-1) is:
  • the compound of Formula (A-1) is: [0427] In some embodiments, the compound of Formula (A-1) is:
  • the compound of Formula (A-1) is: .
  • the present invention provides a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), or Formula (XI).
  • the present invention provides a compound of Formula (I).
  • the present invention provides a compound of Formula (II).
  • the present invention provides a compound of Formula (III).
  • the present invention provides a compound of Formula (IV).
  • the present invention provides a compound of Formula (V).
  • the present invention provides a compound of Formula (VI). In some embodiments, the present invention provides a compound of Formula (VII). In some embodiments, the present invention provides a compound of Formula (VIII). In some embodiments, the present invention provides a compound of Formula (IX). In some embodiments, the present invention provides a compound of Formula (X). In some embodiments, the present invention provides a compound of Formula (XI). [0430] In various embodiments, the present invention provides a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), or Formula (A-4). In some embodiments, the compound of Formula (A-1) is a compound of Formula (A). In some embodiments, the compound of Formula (A-2) is a compound of Formula (A).
  • the compound of Formula (A-3) is a compound of Formula (A).
  • the compound of Formula (A-4) is a compound of Formula (A).
  • the present invention provides a compound of Formula (A).
  • the present invention provides a compound of Formula (A-1).
  • the present invention provides a compound of Formula (A-2).
  • the present invention provides a compound of Formula (A-3).
  • the present invention provides a compound of Formula (A-4).
  • the compounds of the present invention inhibit GIT1.
  • the compounds of the present invention interrupt or inhibit GI1T-MAT2B interaction.
  • the compounds of the present invention interrupt or inhibit GIT1 from interacting with MAT2B and RAF/MEK/ERK. In various embodiments, the compounds of the present invention interrupt or inhibit GIT1 from interacting with MAT2B and RAF/MEK/ERK to halt cancer cell growth. [0432] Embodiments include those listed below. [0433] In various embodiments, the present invention provides a composition comprising a compound of the present invention. In some embodiments, the composition is a pharmaceutical composition.
  • the present invention provides a composition, wherein the composition comprises a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), or Formula (XI), or any combination thereof.
  • the composition is a pharmaceutical composition.
  • the present invention provides a composition, wherein the composition comprises a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A- 3), or Formula (A-4), or any combination thereof.
  • the composition is a pharmaceutical composition.
  • Embodiments include those listed below.
  • the present invention provides a GIT1 inhibitor.
  • the GIT1 inhibitor is a compound of the present invention.
  • the GIT1 inhibitor is a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), or Formula (XI), or a combination thereof.
  • the GIT1 inhibitor is a compound of Formula (I).
  • the GIT1 inhibitor is a compound of Formula (II).
  • the GIT1 inhibitor is a compound of Formula (III).
  • the GIT1 inhibitor is a compound of Formula (IV).
  • the GIT1 inhibitor is a compound of Formula (V). In some embodiments, the GIT1 inhibitor is a compound of Formula (VI). In some embodiments, the GIT1 inhibitor is a compound of Formula (VII). In some embodiments, the GIT1 inhibitor is a compound of Formula (VIII). In some embodiments, the GIT1 inhibitor is a compound of Formula (IX). In some embodiments, the GIT1 inhibitor is a compound of Formula (X). In some embodiments, the GIT1 inhibitor is a compound of Formula (XI). In some embodiments, the GIT1 inhibitor is a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), or Formula (A-4), or any combination thereof.
  • the GIT1 inhibitor is a compound of Formula (A). In some embodiments, the GIT1 inhibitor is a compound of Formula (A-1). In some embodiments, the GIT1 inhibitor is a compound of Formula (A-2). In some embodiments, the GIT1 inhibitor is a compound of Formula (A-3). In some embodiments, the GIT1 inhibitor is a compound of Formula (A-4). [0438] Embodiments include those listed below. [0439] In various embodiments, the present invention provides a pharmaceutical composition comprising a GIT1 inhibitor.
  • the GIT1 inhibitor is a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), or Formula (XI), or a combination thereof.
  • the GIT1 inhibitor is a compound of Formula (I).
  • the GIT1 inhibitor is a compound of Formula (II).
  • the GIT1 inhibitor is a compound of Formula (III).
  • the GIT1 inhibitor is a compound of Formula (IV).
  • the GIT1 inhibitor is a compound of Formula (V).
  • the GIT1 inhibitor is a compound of Formula (VI).
  • the GIT1 inhibitor is a compound of Formula (VII). In some embodiments, the GIT1 inhibitor is a compound of Formula (VIII). In some embodiments, the GIT1 inhibitor is a compound of Formula (IX). In some embodiments, the GIT1 inhibitor is a compound of Formula (X). In some embodiments, the GIT1 inhibitor is a compound of Formula (XI). [0440] In some embodiments, the GIT1 inhibitor is a compound of Formula (A), Formula (A- 1), Formula (A-2), Formula (A-3), or Formula (A-4), or any combination thereof. In some embodiments, the GIT1 inhibitor is a compound of Formula (A). In some embodiments, the GIT1 inhibitor is a compound of Formula (A-1).
  • the GIT1 inhibitor is a compound of Formula (A-2). In some embodiments, the GIT1 inhibitor is a compound of Formula (A-3). In some embodiments, the GIT1 inhibitor is a compound of Formula (A-4). [0441] Embodiments include those listed below.
  • the present invention provides a method of treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject comprising: administering a therapeutically effective amount of an inhibitor of GIT1’s normal interactome to the subject, thereby treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of the condition in the subject, wherein the condition is cancer or a condition associated with an increased expression of GIT1 and MAT2B.
  • the present invention provides a method of treating a condition in a subject comprising: administering a therapeutically effective amount of an inhibitor of GIT1’s normal interactome to the subject, thereby treating the condition in the subject, wherein the condition is cancer or a condition associated with an increased expression of GIT1 and MAT2B.
  • the present invention provides a method of preventing a condition in a subject comprising: administering a therapeutically effective amount of an inhibitor of GIT1’s normal interactome to the subject, thereby preventing the condition in the subject, wherein the condition is cancer or a condition associated with an increased expression of GIT1 and MAT2B.
  • the present invention provides a method of reducing the likelihood of having a condition in a subject comprising: administering a therapeutically effective amount of an inhibitor of GIT1’s normal interactome to the subject, thereby reducing the likelihood of having the condition in the subject, wherein the condition is cancer or a condition associated with an increased expression of GIT1 and MAT2B.
  • the condition is cancer.
  • the condition is hepatocellular carcinoma, colorectal cancer, or cholangiocarcinoma.
  • the condition is hepatocellular carcinoma.
  • the condition is colorectal cancer.
  • the condition is cholangiocarcinoma.
  • the cancer comprises a hepatoblastoma, a cholangiocarcinoma, a colorectal cancer, carcinomas of the breast, lung cancer, oral squamous carcinoma, stomach cancer, or a cancer having an increased expression of GIT1 and MAT2B.
  • the condition is gastrointestinal disease.
  • the present invention provides a method of treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject comprising: administering a therapeutically effective amount of an inhibitor of GIT1 inhibitor to the subject, thereby treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of the condition in the subject.
  • the present invention provides a method of treating a condition in a subject comprising: administering a therapeutically effective amount of a GIT1 inhibitor to the subject, thereby treating the condition in the subject.
  • the present invention provides a method of preventing a condition in a subject comprising: administering a therapeutically effective amount of a GIT1 inhibitor to the subject, thereby preventing the condition in the subject.
  • the present invention provides a method of reducing the likelihood of having a condition in a subject comprising: administering a therapeutically effective amount of a GIT1 inhibitor to the subject, thereby reducing the likelihood of having the condition in the subject.
  • the present invention provides a method of reducing the severity of a condition in a subject comprising: administering a therapeutically effective amount of a GIT1 inhibitor to the subject, thereby reducing the severity of the condition in the subject.
  • the present invention provides a method of slowing the progression of a condition in a subject comprising: administering a therapeutically effective amount of a GIT1 inhibitor to the subject, thereby slowing the progression of the condition in the subject.
  • the condition is cancer.
  • the condition is hepatocellular carcinoma, colorectal cancer, or cholangiocarcinoma.
  • the condition is hepatocellular carcinoma.
  • the condition is colorectal cancer.
  • the condition is cholangiocarcinoma.
  • the cancer comprises a hepatoblastoma, a cholangiocarcinoma, a colorectal cancer, carcinomas of the breast, lung cancer, oral squamous carcinoma, stomach cancer, or a cancer having an increased expression of GIT1 and MAT2B.
  • the condition is gastrointestinal disease.
  • the present invention provides a method of treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject comprising: administering a therapeutically effective amount of a compound of the present invention to the subject, thereby treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of the condition in the subject.
  • the present invention provides a method of treating a condition in a subject comprising: administering a therapeutically effective amount of a compound to the subject, thereby treating the condition in the subject, wherein the compound is a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), Formula (A-4), or combination thereof.
  • the present invention provides a method of preventing a condition in a subject comprising: administering a therapeutically effective amount of a compound to the subject, thereby preventing the condition in the subject, wherein the compound is a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), Formula (A-4), or combination thereof.
  • the present invention provides a method of reducing the likelihood of having a condition in a subject comprising: administering a therapeutically effective amount of compound to the subject, thereby reducing the likelihood of having the condition in the subject, wherein the compound is a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), Formula (A-4), or combination thereof.
  • the present invention provides a method of reducing the severity of a condition in a subject comprising: administering a therapeutically effective amount of compound to the subject, thereby reducing the severity of the condition in the subject, wherein the compound is a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), Formula (A-4), or combination thereof.
  • the present invention provides a method of slowing the progression of a condition in a subject comprising: administering a therapeutically effective amount of compound to the subject, thereby slowing the progression of the condition in the subject, wherein the compound is a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), Formula (A-4), or combination thereof.
  • the condition is cancer.
  • the condition is hepatocellular carcinoma, colorectal cancer, or cholangiocarcinoma.
  • the condition is hepatocellular carcinoma.
  • the condition is colorectal cancer.
  • the condition is cholangiocarcinoma.
  • the cancer comprises a hepatoblastoma, a cholangiocarcinoma, a colorectal cancer, carcinomas of the breast, lung cancer, oral squamous carcinoma, stomach cancer, or a cancer having an increased expression of GIT1 and MAT2B.
  • the condition is gastrointestinal disease.
  • the present invention provides a method of treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject comprising: administering a therapeutically effective amount of a composition to the subject, thereby treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of the condition in the subject, wherein the composition comprises a compound of the present invention.
  • the present invention provides a method of treating a condition in a subject comprising: administering a therapeutically effective amount of a composition to the subject, thereby treating the condition in the subject, wherein the composition comprises a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), Formula (A-4), or combination thereof.
  • the present invention provides a method of preventing a condition in a subject comprising: administering a therapeutically effective amount of a composition to the subject, thereby preventing the condition in the subject, wherein the composition comprises a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A- 3), Formula (A-4), or combination thereof.
  • the present invention provides a method of reducing the likelihood of having a condition in a subject comprising: administering a therapeutically effective amount of a composition to the subject, thereby reducing the likelihood of having the condition in the subject, wherein the composition comprises a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), Formula (A-4), or combination thereof.
  • the present invention provides a method of reducing the severity of a condition in a subject comprising: administering a therapeutically effective amount of a composition to the subject, thereby reducing the severity of the condition in the subject, wherein the composition comprises a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), Formula (A-4), or combination thereof.
  • the present invention provides a method of slowing the progression of a condition in a subject comprising: administering a therapeutically effective amount of a composition to the subject, thereby slowing the progression of the condition in the subject, wherein the composition comprises a compound of Formula (A), Formula (A-1), Formula (A-2), Formula (A-3), Formula (A-4), or combination thereof.
  • the condition is cancer.
  • the condition is hepatocellular carcinoma, colorectal cancer, or cholangiocarcinoma.
  • the condition is hepatocellular carcinoma.
  • the condition is colorectal cancer.
  • the condition is cholangiocarcinoma.
  • the cancer comprises a hepatoblastoma, a cholangiocarcinoma, a colorectal cancer, carcinomas of the breast, lung cancer, oral squamous carcinoma, stomach cancer, or a cancer having an increased expression of GIT1 and MAT2B.
  • the condition is gastrointestinal disease.
  • the present invention provides a kit for treating, preventing, or reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject, comprising: a GIT1 inhibitor of its normal interactome; and instructions for using the GIT1 inhibitor to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of the condition in the subject.
  • the present invention provides a kit for treating, preventing, or reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject, comprising: a GIT1 inhibitor; and instructions for using the GIT1 inhibitor to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of the condition in the subject.
  • the present invention provides a kit for treating, preventing, or reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject, comprising: a composition to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of the condition in the subject; and instructions for using the composition to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of the condition in the subject.
  • the present invention provides a kit for treating, preventing, or reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject, comprising: a compound to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of the condition in the subject; and instructions for using the compound to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of the condition in the subject.
  • a kit for treating, preventing, or reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject comprising: a compound to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of the condition in the subject; and instructions for using the compound to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of the condition in the subject.
  • Embodiments include those listed below.
  • the present invention provides a use of a compound of the present invention.
  • the present invention provides a
  • the present invention provides a use of a composition of the present invention.
  • the present invention provides a use of a composition of the present invention as a medicament.
  • EXAMPLES [0479] The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. One skilled in the art may develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.
  • Compound C3 was PubChem Compound ID#663383 (2-(8,8-Dimethyl-4-oxo-7,10- dihydro-8H-pyrano[3’’,4’’:5’,6’]pyrido[3’,2’:4,5]thieno[3,2-d]pyrimidin-3(4H)-yl)-N-(2- furylmethyl)acetamide).
  • Example 1 Determining domain at which MAT2B binds to GIT1.
  • the present invention provides cancer treatments by using a compound to inhibit GIT1 interaction with MAT2B. A general scheme is shown in FIG.2.
  • FIG.3 reveals that FLAG-GIT1 (1-635aa) and FLAG-GIT1 (250-770aa) pulled down endogenous MAT2B successfully, but FLAG-GIT1 (420-770aa) did not.
  • 250-420aa of GIT1 which corresponds to the SHD domain, is where MAT2B binds.
  • the inventors discovered the SHD domain is inaccessible, so the ANK domain was chosen as the target for small inhibitory molecules instead.
  • Example 2 [0482] Treatment of colorectal cancers (CRC) and hepatocellular carcinoma (HCC) by novel compounds and methods that inhibit GIT1 interaction with MAT2B to reduce activation of RAS- RAF-MEK-ERK signaling that enhances tumor growth and invasion.
  • CRC colorectal cancers
  • HCC hepatocellular carcinoma
  • the inventors identified nine inhibitors and perfomed an EdU assay after treating non- malignant (HEK293, AML12) and malignant (HepG2, MzChA-1, HT-29, RKO) cells with varying concentrations of GIT1 inhibitor for 24 hours (results are mean ⁇ SE from 3 independent experiments done in duplicates, *p ⁇ 0.05 vs. DMSO).
  • An MTT assay was also performed after treating primary human and mouse hepatocytes and liver and colon cancer cells with varying concentrations of GIT1 inhibitor for 24 hours (results are mean ⁇ SE from 3 independent experiments done in duplicates, *p ⁇ 0.05 vs. DMSO). The results are shown in FIGS. 4 and 5.
  • Compound C3 exhibited the most potent growth inhibitory effect and was cytotoxic in cancer cells at 10 ⁇ M but not in non-malignant cells. Percoll may be used to remove dead human hepatocytes.
  • Example 3 In vitro and in vivo studies on exemplary GIT1 inhibitors [0484] Compound C3 was dissolved in pure DMSO at 100mM as stock, then dissolved in DMSO to 10mM when used. This solution was added to culture dishes at a final concentration of 1-10 ⁇ M as needed for experiments.
  • FIG.6 shows results of a binding assay with flow cytometry for HEPG2 and AML12 cells synchronized by serum starvation for 48 hours and released into serum containing media and treated with 1-5 ⁇ M of a GIT1 inhibitor (compound C3) or DMSO control for 24 hours prior to FACS (results are from representative experiments, done independently at least three times; *p ⁇ 0.05 vs. DMSO).
  • FIG.7 shows results of a binding assay with flow cytometry for RKO and HEK293 cells synchronized by serum starvation for 48 hours and released into serum containing media and treated with 1-5 ⁇ M of a GIT1 inhibitor or DMSO for 24 hours prior to FACS (results are from representative experiments, done independently at least three times; *p ⁇ 0.05 vs. DMSO).
  • treatment with compound C3 lowered the percentage of cells in G1 phase, while G2/M phase was significantly increased, suggesting G2/M phase arrest in cancer cells. This did not occur with AML12 or HEK293 cells.
  • FIG.9 shows results of a migration assay of RKO cells treated with 1-2 ⁇ M compound C3 for 24 hours (results are from representative experiments done at least three times. *p ⁇ 0.05 vs. DMSO).
  • compound C3 inhibited the clonogenic potential of both cancer cell types at 1 ⁇ M and the effect was dose dependent but had no effect on clonogenic potential of AML12 cells.
  • FIG. 10 shows results of a migration assay of RKO cells treated with 1-2 ⁇ M compound C3 for 24 hours (results are from representative experiments done at least three times. *p ⁇ 0.05 vs. DMSO).
  • FIG. 11 shows the blots and densitometric changes from treating HepG2 cells with 10 ⁇ M of a GIT1 inhibitor for 24 hours and co-IP with anti-MAT2B (left) or anti-GIT1 (right) antibodies followed by immunoblotting (results are from at least 3 independent experiments in mean ⁇ SE. *p ⁇ 0.05 vs. DMSO).
  • FIG.13 shows the blots and densitometric changes from treating AML12, HepG2, and MC38 cells with 10 ⁇ M of a GIT1 inhibitor for 24 hours followed by western blotting (results are from at least 3 independent experiments in mean ⁇ SE. *p ⁇ 0.05 vs. DMSO).
  • FIG. 14 shows the blots and densitometric changes from treating AML12, HepG2, and RKO cells with 2-10 ⁇ M of a GIT1 inhibitor for 24 hours followed by western blotting (results are from at least 3 independent experiments in mean ⁇ SE. *p ⁇ 0.05 vs. DMSO).
  • FIG. 16A shows cyclin B1 expression by RT-PCR and (FIG.16B) Western Blotting. Numbers shown below are mean ⁇ SE densitometric values.
  • 16C shows results for cells that were pretreated with cycloheximide (CHX) and then with DMSO or a GIT1 inhibitor (5 ⁇ M) in time course (results are from at least 3 independent experiments in mean ⁇ SE. *p ⁇ 0.05 vs. DMSO). Effect of Compound C3 on cyclin B1/CDK1 interaction and CDK1 activation [0491] HepG2 and RKO cells were treated with 5 ⁇ M of compound C3 for 24 hours, followed by co-IP with anti-CDK1 antibody and western blots. Results can be seen in (FIG.17A) and (FIG.
  • FIG. 17B shows results of treating AML12, MC38, and HepG2 cells with 2-10 ⁇ M of a GIT1 inhibitor for 24 hours and western blotting for pCDK1 (Thr14/Tyr15), total CDK1 and Actin.
  • FIG. 17C shows results of treating HepG2 cells with a GIT1 inhibitor for 24 hours and western blotting for p-cyclin B1 (S116).
  • the densitometric changes are from at least 3 independent experiments in mean ⁇ SE; *p ⁇ 0.05 vs. DMSO. Binding of cyclin B1 to CDK1 initiates conformational changes allowing CDK1 to alter its phosphorylation status and to become an active kinase.
  • treatment with compound C3 activated cyclin B1/CDK1, led to cyclin B1 accumulation by a mechanism that requires GIT1.
  • FIG.19A shows gross tumor appearance at day 13 and growth curve;
  • FIG.19B representative H&E staining of tumors;
  • FIG.19C TUNEL staining and score;
  • FIG. 19D PCNA staining and score; and
  • FIG. 19E western blotting of representative tumors (*p ⁇ 0.05, ⁇ p ⁇ 0.01 vs. DMSO).
  • DMSO was dissolved in 200 ⁇ l 0.9% saline to reach 25 mg/kg.
  • DMSO was dissolved in 200 ⁇ l saline to achieve a concentration of DMSO in saline of 7.5%.
  • RKO cells (2x106) stably expressing luciferase were injected directly into the liver of nude mice. Twenty days later DMSO and Compound C3 were injected intraperitoneally (ip) at a dose of 25mg/kg daily for 5 days and imaged on day 7.
  • FIG.20A showssmall animal imaging using IVIS Spectrum photon-counting device optical imaging system (Xenogen, Alameda, CA) at day 0 and 7 after start of treatment to track tumor progression;
  • FIG.20B a graph summarizing luciferase intensity;
  • FIG. 20C gross pictures of the livers at day 7, with arrows pointing to tumors (*p ⁇ 0.05).
  • Compound C3 was effective in reducing tumor growth in this model without causing overt toxicity. Effect of Compound C3 on CRC liver metastasis in immune competent mice [0495]
  • Compound C3 powder was dissolved in pure DMSO at 50 mg/ml, as a stock store in - 80°C.
  • FIG.21A shows small animal imaging after treatment started; (FIG. 21B) H&E of tumors; (FIG.
  • FIG. 21C shows results of gating CD45+ for leucocytes; and then gating F4/80+CD11b+ for macrophages. In this subgroup, CD206+ was used to identify M2 macrophages.
  • Compound C3 dramatically reduced M2 macrophages in the tumors.
  • Effect of Compound C3 on growth of CRC organoid [0497] An EdU assay of CRC organoids from AKPS mice (APCF/Fp53F/FKRAS+SMAD4KOCDX2ERT+) was treated with 10 ⁇ M of compound C3 for 24 hours. Low and high magnifications, as seen in FIG.
  • GIT1 WT was mutated at proline 730, 731, 733, and 736 residues to alanine (PPEPGAPVD (SEQ ID NO:1) ⁇ AAEAGAAVD (SEQ ID NO:2)) (GIT1mut) and overexpressed in RKO cells for 48 hours, followed by co-IP with anti-cyclin B1 antibody and blotting for cyclin B1 and GIT1.
  • Compound C38 was prepared according to the general synthetic approach shown in FIG.43. RKO IC 50 > 25 uM. HepG2 IC 50 > 50 uM.
  • Example 7 Synthesis of Compound C39 Compound C39 [0501] Compound C39 was prepared according to the general synthetic approach shown in FIG.43. RKO IC 50 > 50 uM. HepG2 IC 50 > 25 uM.
  • Example 8 Effects of Compound C33 on MTT in RKO and HepG2 Cells [0502] MTT assay showed Compound C33 has (sub-micromolar) potentcy against RKO and HepG2 (IC 50 0.98 and 0.83 uM, respectively (FIG. 42).
  • Compound C33 has improved (sub- macromolar) potentcy against RKO and HepG2 over that of Compound C3 (RKO/HepG2 IC 50 ca. 20 uM) with no toxicity in human or mouse hepatocytes (data not shown).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention décrit des composés qui inhibent GIT1. L'invention décrit en outre des compositions contenant ces inhibiteurs de GIT1, ainsi que des procédés et des kits utilisant ces inhibiteurs de GIT1 pour traiter diverses affections médicales. Les affections médicales pouvant être traitées par les différents modes de réalisation de l'invention comprennent, de manière non restrictive, les cancers et les tumeurs.
EP23887073.7A 2022-11-04 2023-11-03 Composés et méthodes de traitement de cancers Pending EP4611749A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263422672P 2022-11-04 2022-11-04
PCT/US2023/078657 WO2024097972A2 (fr) 2022-11-04 2023-11-03 Composés et méthodes de traitement de cancers

Publications (1)

Publication Number Publication Date
EP4611749A2 true EP4611749A2 (fr) 2025-09-10

Family

ID=90931674

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23887073.7A Pending EP4611749A2 (fr) 2022-11-04 2023-11-03 Composés et méthodes de traitement de cancers

Country Status (2)

Country Link
EP (1) EP4611749A2 (fr)
WO (1) WO2024097972A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
WO2017045689A1 (fr) * 2015-09-14 2017-03-23 Pentabase Aps Procédés et matériaux pour la détection de mutations

Also Published As

Publication number Publication date
WO2024097972A3 (fr) 2024-07-25
WO2024097972A2 (fr) 2024-05-10

Similar Documents

Publication Publication Date Title
AU2021201667B2 (en) Compositions and methods for treating cancers
US20210085649A1 (en) Methods and use of compounds that bind to rela of nf-kb
US20220257767A1 (en) Ionic liquids for drug delivery
TW202342480A (zh) 化合物及其用途
WO2024097972A2 (fr) Composés et méthodes de traitement de cancers
EP3999065B1 (fr) Compositions thérapeutiques et procédés comprenant idelalisib and defactinibde traitement de cancers du sein
WO2025255237A1 (fr) Utilisation d'inhibiteurs d'atr en combinaison avec une thérapie par radioligand pour le traitement du cancer
WO2025188783A1 (fr) Compositions thérapeutiques et procédés de traitement de cancers
HK1238131B (zh) 用於治疗癌症的组合物
HK1238131A1 (en) Compositions for treating cancers

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250502

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)